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ABSTRACT
Histamine and serotonin are important biogenic amines that regulate vital brain
functions. These two transmitters are thoughts to be involved in neurodegenerative
diseases such as Parkinson’s and Alzheimer’s and affective disorders including
depression. Histamine and serotonin are believed to regulate each other but their
fundamental neuromodulation mechanisms are not well understood. This lack of
understanding makes brain disorders implicating these two transmitters difficult to
diagnose and treat. Our lab extensively investigates the serotonergic system to understand
serotonin’s neurochemistry in the brain. However, histamine is relatively understudied
with respect to other biogenic amines because of an absence of suitable analytical tools.
This work introduces a strategic approach to overcome this analytical challenge and
investigates the real-time neuromodulation of in vivo histamine and serotonin to
understand physiological functions in healthy and disease states using fast-scan cyclic
voltammetry (FSCV). First, we perform a proof-of-principle study of Copper (Cu(II))
analysis to characterize the adsorption driven FSCV response. Next, we employ FSCV to
develop a novel voltammetric method to selectively and sensitively monitor real-time in
vivo histamine and serotonin neurotransmissions in the posterior hypothalamus (PH).
This study reveals that histamine inhibits serotonin via an H3 receptor mediated process,
highlighting histamine’s roles in regulating serotonin release in the brain. Following that,
we examine histamine’s reuptake mechanisms via monoamine transporter proteins and
demonstrate that histamine uptake mechanism is mediated by organic cation transporters.
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Finally, we use our novel FSCV method to monitor histamine and serotonin
neurotransmissions in HIV- 1 Tg rats, which exhibit neuroinflammation, to understand
impaired neurochemical mechanisms in the disease state. Collectively, this dissertation
showcases a novel and robust electroanalytical strategy to simultaneously monitor in
vivo histamine and serotonin neuromodulation in real time. Innovative discoveries in this
systematic investigation of the histaminergic regulation of serotonin in diverse
neurochemical and pathophysiological processes will pave the way towards more
efficient therapies for histamine and serotonin related brain disorders.
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CHAPTER 1
INTRODUCTION
1.1 Neuromodulation of Histamine and Serotonin
Histamine is an important biogenic amine which modulates vital brain functions1-3
by regulating other neurotransmitters, in particular serotonin4,5. These two chemical
messengers co-exist in multiple brain regions6,7 and are implicated in many brain
dysfunctions such as Parkinson’s8-10 and Alzheimer’s diseases11,12 and mood
disorders13,14. Lack of knowledge regarding histamine and serotonin neuromodulation
mechanisms makes such brain disorders hard to diagnose and cure. Our lab widely
investigates the serotonergic system to understand the complex neurochemistry of this
molecule using electroanalytical tools15,16. However, histamine neurochemistry has been
relatively understudied with respect to serotonin. It is desirable, therefore, to study in vivo
neuromodulation of these two neurotransmitters to understand their functions in healthy
and disease states. To date, this topic has been challenging due to the absence of
appropriate analytical tools. This dissertation illustrates the development of a novel
voltammetric method to monitor, in real-time, the modulatory profile of these two
messengers. The serotonergic and histaminergic systems are discussed in the first part of
this chapter. The second portion describes existing electroanalytical techniques to
monitor in vivo neurotransmissions, while the latter part of the chapter focuses on method
development toward in vivo histamine-serotonin detection.
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1.1.1 The Serotonergic System
Serotonin is a vital neurotransmitter that is implicated in mood and emotional
brain functions17. Dysregulation of this chemical messenger in the brain causes several
neurological disorders such as anxiety and depression13,14. Therefore, serotonin has been
the main focus of depression and antidepressant drug related studies13. However, the tight
regulation of in vivo serotonin in the brain creates limitations for analytical tools to
monitor rapid serotonin neurotransmissions. Despite limited selectivity, differential pulse
voltammetry and chronoamperometry studies have brought forth noteworthy information
about in vivo serotonin dynamics18,19. In 2009 Hashemi et al. employed fast-scan cyclic
voltammetry (FSCV) to detect in vivo stimulated serotonin release in the rat substantia
nigra pars reticulate (SNr) as a more selective and robust method20.
With this method, our lab primarily concentrates on in vivo serotonin
neurotransmission in depression and autism spectrum disorder. The Hashemi lab has been
studying endogenous serotonin release and reuptake mechanisms using FSCV. For
instance, our lab confirmed that the serotonin system consists of two distinct reuptake
mechanisms and found a prolonged inhibitory role for serotonin autoreceptors16.
Histamine has been previously thought to modulate serotonin4. Therefore, I became
interested in investigating histamine and serotonin neuromodulation. More details about
the histaminergic system are presented in the next section.
1.1.2 The Histaminergic System
Histamine is a monoamine neurotransmitter which regulates important brain
functions such as circadian rhythm and inflammation3. Histamine is synthesized from the
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amino acid histidine via decarboxylation by the histidine decarboxylase enzyme21.
Neuronal histamine is stored in cell somas and neuroeffector junctions22,23. Like other
biogenic amines, this transmitter is packaged into vesicles by vesicular monoamine
transporters and released upon the action potential activation24. However unlike other
biogenic amines, there is no known active transport mechanism for histamine25,26.
Therefore, enzymatic degradation is thoughts to be the primary means of histamine
inactivation via the N-methyltransferase enzyme27,28. Tele-methylhistamine, the product
of the histamine degradation, undergoes further degradation to t-methyl-imidazoleacetic
acid via monoamine oxidase29.
Past studies have identified four histamine receptors, namely the H1, H2, H3, and
H4 receptors. All receptors are rhodopsin-like G-protein coupled receptors3. Histamine
neurons are excited through H1 receptor activation and H1 receptor dysfunction leads to
immunological and behavioral abnormalities30. H1 receptor antihistaminergic agents
inactivate the H1 receptors and break signal propagation31. Distribution of the H2
receptors is more consistent and widespread in the rodent brain32. Dysregulation of this
receptor is associated with cognitive impairments33. Activation of the H3 autoreceptor,
which is an inhibitory feedback receptor on the presynaptic histamine neuron, inhibits
histamine release and synthesis34,35. Additionally, this presynaptic receptor controls the
release of other neurotransmitters, including glutamate, acetylcholine, and serotonin3,25.
Loss of H3 receptor function is related to abnormalities in locomotion, behavior, and
weight36,37. H4 receptors exhibit properties similar to the H3 receptors but are expressed in
the peripheral system38.
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Recent studies have shown that irregularities of the histaminergic system cause
abnormalities in neuroendocrine and higher brain functions. Histamine levels are
significantly increased in the brains of Parkinson’s patients8,10. The degeneration of
histaminergic fibers in the tuberomammillary nucleus (TMN), as well as globally lowered
neuronal histamine levels, are well-documented in Alzheimer’s disease11. Moreover,
histamine is a key biomarker of inflammation which is comorbid with many brain
disorders39,40. Also, a recent study has illustrated that histamine may promote anxiety,
while lesions of the TMN reduce symptoms41. Interestingly, histamine neurons in TMN
are related to neuroendocrine signals concerned with mood disorders like depression33,42.
This relationship between histamine and depression is appealing to our lab since we
primarily concentrate on serotonin, which is the transmitter most highly implicated in
depression and anxiety.
Therefore, I find it of great significance to direct my efforts to study in vivo
histamine and serotonin modulation. However, studying this neuromodulation
mechanism has been challenging due to the absence of suitable analytical techniques,
which can simultaneously monitor these two chemical messengers in vivo. An ideal
method should encompass: sensitivity for low neurotransmitter concentrations, selectivity
for

different

neurotransmitters,

adequate

speed

for

monitoring

sub-second

neurotransmission and appropriate probes for real-time in vivo measurements.
Electroanalytical techniques and how they address these challenges are described in the
next section.
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1.1.3 Detection and Quantification of Neurotransmitters
Monitoring the brain’s chemicals and neurotransmitters necessitates specific
requirements. First, brain signaling events occur on a sub-second time scale. Thus, the
temporal resolution of the method should be sufficient to monitor these events. Secondly,
the brain is physically delicate thus the technique should be minimally invasive. Third,
neurotransmitters and their metabolites are chemically similar, which means the tool must
have a high degree of selectivity to distinguish between species. Lastly, neurotransmitters
are present at very low concentrations in the synapse. Accordingly, an ideal detection
method must display excellent sensitivity.
Carbon fiber microelectrodes (CFMs) are biocompatible, robust, stable, and cause
minimal damage to the brain tissue. They also have favorable and fast surface kinetics for
sensitive measurements43. Moreover, the large surface area due to the rough exterior of
the carbon surface allows for more adsorption as shown in Figure 1.1. Undoubtedly,
combining CFMs with electroanalytical techniques permits the quantification of
electroactive neurotransmitters in the brain, in real time.

Carbon Fiber
Glass Seal

Figure 1.1. SEM image of a carbon-fiber microelectrode
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1.1.4 CFMs and Electroanalytical Techniques
Some monoamine, like dopamine, serotonin, histamine and adenosine, are
electroactive. Therefore, the dynamics of these electroactive messengers can be studied
using electroanalytical techniques in vivo as described below.
Amperometry works by holding the CFM at a potential that is more positive than
the analyte’s oxidation potential. The resulting continuous oxidation produces a current
which is used to quantify the neurotransmitters around the electrode. This method has
been developed to monitor exocytosis in a single cell44. Moreover, the flexibility of
CFMs makes it feasible to build microelectrode arrays. For instance, the Ewing group has
been using a 16-electrode array to monitor exocytosis from a single cell45. Amperometry
is a sophisticated technique to measure chemical messengers. However, selectivity is
inadequate for monitoring neurotransmission in complex media, because the constant
potential oxidizes all electroactive analytes below the applied potential.
Chronoamperometry has been developed to overcome the selectivity problem
with amperometry. This method uses a square wave (between defined potential limits) to
CFMs at 5-25 Hz. The square wave generates a large capacitative current at the step
functions, which decays exponentially over time. Chronoamperometry can provide the
selectivity required, to some degree, by taking a ratio of oxidative and reductive currents.
This method has been using to study Parkinson’s disease46, depression47, addiction48, and
transporter kinetics49. Collectively, chronoamperometry can successfully monitor
neurotransmitter clearance, although more selectivity is required to monitor various
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neurotransmissions in vivo. The next section describes FSCV as a robust and selective
electrochemical technique to monitor real-time in vivo neurotransmission.
1.2 Fast-Scan Cyclic Voltammetry (FSCV)
Julian Milar and colleagues first presented FSCV to detect electroactive
neurotransmitters in the mid-20th century50. Over several decades, FSCV has been
emerging as an electroanalytical technique on diverse frontiers. Primarily, FSCV has
been utilized to monitor real-time dopamine dynamics51,52. Our lab has pioneered the
application of FSCV to serotonin, histamine53, Cu(II)54 and Pb(II)55. FSCV employs high
scan rates (100 Vs-1 to 1500 Vs-1) at a frequency of 10 Hz, whereas traditional cyclic
voltammetry uses mVs-1 scan rates. Therefore, with the higher scan rates employed in
FSCV, a single data set is collected within milliseconds, which raises the temporal
resolution to the sub-second scale. However, high scan rates also produce large nonfaradaic currents at the electrode surface, which mask the faradaic signal. Therefore,
FSCV is modified to integrate background subtraction to remove this non-faradaic signal.
As a result of background subtraction, FSCV can only detect changes. Therefore,
stimulation is used to evoke neurotransmitter release in vivo.
In FSCV, the CFM is held at a resting potential between cycles, allowing
neurotransmitters to adsorb onto the carbon surface. During the anodic wave, which
ramps up from the resting potential to a positive potential limit, adsorbed analytes will be
oxidized on the electrode surface; likewise, during the cathodic wave analytes will be
reduced. This potential vs. time instruction is known as a FSCV waveform and the
resulting faradaic events generate electron flow through the electrode, measurable as a
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current. After background subtraction, FSCV generates an analyte specific cyclic
voltammogram (CV), that can be used for qualitative and quantitative analysis. For data
interpretation purposes, a 2D plot, also known as color-plot, is digitally constructed by
stacking a set of CVs collected at 10 Hz for a limited time of period. Quantitative data
along the time axis is provided by extracting horizontal data points along the event.
Serotonin detection is challenging with FSCV because serotonin’s metabolites
foul the electrode surface. However, a thin coating of Nafion, a cation exchange polymer,
overcomes this fouling issue20. Figure 1.2 illustrates the stimulated release of serotonin
in the CA2 region of the hippocampus medial forebrain bundle (MFB) stimulation.
Figure 1.2A shows a representative data color plot. The discrete green event around 0.7
V demonstrates serotonin oxidation. A typical serotonin CV is presented inset in the color
plot. Figure 1.2B represents [serotonin] vs. time event upon stimulation.

Figure 1.2. The stimulated release of serotonin in mouse hippocampus CA2. (A)
representative color plot. Inset shows a classic serotonin CV extracted from the vertical
white dashed line. (B) illustrates a [serotonin] vs. time response obtained from the
horizontal dashed line along the peak serotonin oxidation event.
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1.2.1 Expanding the Scope of FSCV
Histamine56, adenosine57 and H2O258 have similar CVs because their oxidation
peaks appear on the cathodic wave. Thus, their identities have only been tested via
pharmacological approaches. Modification of the FSCV waveform can permit these
neurotransmitters to be monitored more selectively without pharmacological verification.
Developing a FSCV method to monitor several neurotransmitters simultaneously is
challenging but would provide critical information about their modulatory mechanisms in
the brain.

Figure 1.3. (A) Representative color plot for simultaneous detection of histamine and
serotonin in mouse posterior hypothalamus. (B) CV extracted from the vertical white
dashed line at the histamine event. (C) [histamine] and [serotonin] vs. time obtained from
horizontal dashed line along both events. The blue bar right underneath the color plot and
in (C) represents the stimulation.
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Figure 1.3A illustrates a representative color plot for simultaneous detection of
histamine and serotonin in mouse posterior hypothalamus (PH). I developed this novel
FSCV waveform that detects both the oxidation of histamine and serotonin
simultaneously53,59. FSCV recognizes histamine releases (green event), which is denoted
by white horizontal dashed line labeled “histamine”, in PH upon stimulation of the MFB
as shown in the Figure 1.2A. A subsequent serotonin event appears (blue event right
above histamine event) with a slight delay as denoted by a white dashed line labeled
“serotonin” in the color plot. Figure 1.2B represents the unique CV that is extracted from
the vertical dashed line along the events, and histamine oxidation appears around 0.3 V
whereas inverse serotonin oxidation occurs around 0.8 V. This inverse oxidation
(negative event) illustrates the reduction of ambient serotonin concentration after the
stimulation. Figure 1.1C shows [histamine] and [serotonin] vs. time responses obtained
from the horizontal dashed lines along both events in the color plot and these traces
demonstrate real-time histaminergic modulation of serotonin. This novel method can be
used to investigate in vivo histamine and serotonin to define their roles in healthy and
pathophysiological states.
This dissertation presents a systemic approach to developing a novel
electrochemical tool for simultaneous detection of in vivo histamine and serotonin, as
described below.
1.3 Scope of the Dissertation
In this dissertation, I first used Cu(II) metal analysis to understand the adsorption
driven FSCV response (Chapter 2). Using that knowledge, I then developed a novel
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FSCV method to selectively and sensitively monitor histamine neurotransmission in the
mouse posterior hypothalamus (Chapter 3). This work was extended to simultaneously
monitor histamine and serotonin in real time to study their neuromodulation in the brain
(Chapter 4). Since an active reuptake mechanism for histamine has not been identified, I
then utilized our novel method to study histamine reuptake mechanisms via monoamine
transporter proteins (Chapter 5). Finally, I used our novel FSCV method to investigate
histaminergic regulation of serotonin during disease using HIV-1 Tg rats which exhibit
neuroinflammation (Chapter 7). The outline of this dissertation is described below.
Chapter 1: Introduction
Chapter 2: This chapter describes the underlying fundamental mechanism of adsorption
driven FSCV responses. We demonstrated the progression of the FSCV response from
the classical cyclic voltammetry response using the Cu(II) analysis. Finally, we proved
that adsorption of Cu(II) onto the CFM surface follows a Langmuir adsorption isotherm.
Chapter 3: In this chapter, we optimized an electrochemical waveform that provided a
stimulation-locked and unique electrochemical signal for histamine. Then, we described
in vitro waveform optimization and in vivo detection of the stimulated release of
histamine in the mouse PH via electrical stimulation in the MFB. Finally, this chapter
demonstrated that a robust signal can be used to describe histamine's in vivo dynamics.
Chapter 4: This chapter describes a voltammetric approach to simultaneous monitoring
of histamine and serotonin in real time. We found that serotonin was rapidly and potently
inhibited by histamine release in a concentration-dependent manner. Lastly, we
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developed mathematical models and performed pharmacological experiments to verify
that this serotonin inhibition was mediated by H3 receptors.
Chapter 5: In this section, we employed a previously described FSCV method (chapter
4) to investigate histamine reuptake kinetics pharmacologically. Moreover, this section
provides evidence for organic cation transporter mediated histamine uptake. We also
found that histamine reuptake mechanism were inhibited by commercially available
antidepressant drugs: escitalopram, citalopram, and desipramine.
Chapter 6: This chapter illustrates fundamental neurochemical changes in serotonin and
histamine in HIV-1 Tg rats, which display neuroinflammation. We employed FSCV to
interpret impaired neurotransmissions and found that histamine release was elevated in
HIV-1 Tg rats which in turn inhibited more serotonin compared to the control animals.
Chapter 7: The final chapter summarizes the conclusions of this research work and
highlights the future directions.
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CHAPTER 2
FAST VOLTAMMETRY OF METALS AT CARBON-FIBER
MICROELECTRODES: COPPER ADSORPTION ONTO ACTIVATED
CARBON AIDS RAPID ELECTROCHEMICAL ANALYSIS

Reprinted with permission from Royal Society of Chemistry.
Pathirathna P, Samaranayake S, Atcherley CW, Parent KL, Heien ML, McElmurry SP,
Hashemi P (2014) Fast voltammetry of metals at carbon-fiber microelectrodes: copper
adsorption onto activated carbon aids rapid electrochemical analysis. Analyst 139:46734680. I contributed both experimentally and intellectually and the results of this project
directed me to my next project.
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2.1 Abstract
Rapid, in situ trace metal analysis is essential for understanding many biological
and environmental processes. For example, trace metals are thought to act as chemical
messengers in the brain. In the environment, some of the most damaging pollution occurs
when metals are rapidly mobilized and transported during hydrologic events (storms).
Electrochemistry is attractive for in situ analysis, primarily because electrodes are
compact, cheap and portable. Electrochemical techniques, however, do not traditionally
report trace metals in real-time. In this work, we investigated the fundamental
mechanisms of a novel method, based on fast-scan cyclic voltammetry (FSCV), that
reports trace metals with sub-second temporal resolution at carbon-fiber microelectrodes
(CFMs). Electrochemical methods and geochemical models were employed to find that
activated CFMs rapidly adsorb copper, a phenomenon that greatly advances the temporal
capabilities of electrochemistry. We established the thermodynamics of surface copper
adsorption and the electrochemical nature of copper deposition onto CFMs and hence
identified a unique adsorption-controlled electrochemical mechanism for ultra-fast trace
metal analysis. This knowledge can be exploited in the future to increase the sensitivity
and selectivity of CFMs for fast voltammetry of trace metals in a variety of biological
and environmental models.
2.2 Introduction
Trace metal analysis in real-time is essential for understanding many biological
and environmental processes. For example, trace metals have important functions in
biology and are garnering new attention for their roles as neurotransmitters1,2. In
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Alzheimer’s disease for example, copper accumulates in -amyloid plaques3. It is thought
that this copper build-up comes at the expense of its normal roles as a neurotransmitter,
accounting for some of the disease’s neurological deficits3,4. It has been impossible to
chemically monitor endogenously acting copper to verify this hypothesis, primarily
because chemical transmission occurs so quickly (< seconds).
Rapid metal analysis is also important in the environment, particularly in natural
water systems where trace metal contamination is extremely hazardous5. The welldocumented health consequences of trace metal exposure6-9 are exacerbated because
metals bioaccumulate in plants and animals10-13, providing numerous exposure paradigms
for humans. Anthropogenic sources of trace metals are commonly mobilized and
transported during hydraulic events (storms)14. It is critical to characterize aquatic trace
metals in real-time because their interactions with organic ligands and soils are fast (<
seconds)15. Such rapid metal detection would provide the most efficient implementation
of existing metal mitigation systems 16-21 via a diagnostic approach.
Most analytical techniques cannot monitor metals rapidly (< seconds).
Spectroscopic techniques are sensitive and selective22, however sample collection and
preparation can alter metal speciation and make dynamic measurements difficult23,24.
Electrochemical methods are attractive because the chemistry occurs at a submersible or
integrated surface that minimally impacts its surroundings. Ion-selective electrodes have
a temporal resolution of seconds;25,26 however it is typically challenging to make
measurements in dynamically changing matrices. Stripping voltammetries (such as
anodic stripping and adsorptive stripping voltammetry) have extremely high
sensitivities27. This high sensitivity is largely due to a lengthy pre-concentration step
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(minutes)

that

decreases

temporal

resolution28-30.

Moreover,

anodic

stripping

voltammetry is most commonly performed at Hg electrodes31 which have limited
portability and pose their own toxicity concerns.
We recently described the use of carbon-fiber microelectrodes (CFMs) to detect
copper (II) (Cu2+) and lead (II) (Pb2+) with fast scan cyclic voltammetry (FSCV) at scan
rates of 300 – 600 Vs-1 32,33. Our ultra-fast, Hg-free method can quantify Cu2+ and Pb2+
concentration changes every 100 ms with parts per billion and parts per million
sensitivity, respectively32,33. Our method is highly applicable for studying metals in real
time. However it is essential to describe the fundamental mechanisms of this fast
voltammetric method before it can be developed into a routine analytical tool for
biological and environmental applications. In this paper therefore, we take a multifaceted approach and establish the underlying mechanisms of fast voltammetry of Cu2+
on CFMs in established laboratory test solutions.
We analyzed Cu2+, a biologically relevant2 and environmentally problematic
metal ion34 with well-known redox chemistry35,36. Besides classical nucleation, growth
and stripping features36, we observed new, additional peaks in Cu2+ slow scan cyclic
voltammograms. These additional peaks were not diminished, as the classical features
were, when the scan-rate was increased. In fact, with increasing scan rate, the new
features were augmented, as seen previously with neurotransmitters adsorbed to CFM
surfaces37. We therefore investigated surface adsorption as a fundamental mechanism of
the Cu2+ FSCV signal. We utilized electrochemical, geochemical, and microscopic tools
to describe CFM’s surface and thermodynamic mechanisms towards Cu2+. This study
provides valuable insight into the adsorption chemistry that governs the FSCV response
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to metals. Our findings are critical to the future development of the method, namely
increases in sensitivity and selectivity, in application to real samples.
2.3 Experimental Section
2.3.1 Solutions
Cu2+ solutions were prepared by dissolving Cu(NO3)2 in NaCl (0.01 M) and in tris
buffer (15 mM tris(hydroxymethyl)aminomethane), 140 mM NaCl, 3.25 mM KCl, 1.2
mM CaCl2, 1.25 mM NaH2PO4, 1.2 mM MgCl2 and 2.0 mM Na2SO4). All chemicals
were purchased from Sigma-Aldrich (St. Louis, MO). At room temperature and pressure,
the pH of Cu2+ in NaCl and tris buffer solutions was ~5.5 and 7.4 respectively.
2.3.2 Microelectrodes
CFMs were prepared by vacuum aspirating a single carbon fiber of 5 µm radius
(T-650, Cytec Industries, NJ) into a glass capillary (0.6 mm external diameter, 0.4 mm
internal diameter, A-M Systems, Inc., Sequim, WA). The capillary was pulled under
gravity with a micropipette puller (Narishige, Tokyo, Japan) leaving a tapered end to
form a carbon-glass seal. The exposed end of the carbon fiber was cut to approximately
150 µm under a microscope. Gold microelectrodes (AuMs) were prepared as described
above but with a gold microwire of 10 µm radius (Goodfellow Co, PA), cut to
approximately 150-200 µm.
2.3.3 Cyclic Voltammetry
All voltammetry employed a 2-electrode system. Cyclic voltammograms were
collected on 5 different electrodes and representative examples are displayed. For slow
scan cyclic voltammetry (scan rates ≤ 100 mVs-1), microelectrodes were placed into a
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constantly stirred solution of Cu(NO3)2 and a triangular wave form (+1 V to –1 V) was
applied using custom software, Wildcat CV, written in LAB-VIEW 2012 (National
Instruments, Austin, TX). Only solutions for slow scan cyclic voltammetry were
nitrogen-purged prior to experimentation. The reference electrode was fabricated by
electroplating Cl– on a Ag wire (A-M systems, WA). For scan rates above 1 Vs-1, inhouse software, WCCV 2.0, written in LABVIEW 2012 collected background-subtracted
voltammograms in a flow-injection analysis system.
2.3.4 Electrochemical Pre-treatment
For most experiments microelectrodes were electrochemically pre-treated with a
Cu2+ sensitive triangular waveform as previously described.33 For experiments comparing
electrochemical and chemical pretreatments, the anodic potential/rest potential of the
CFMs was varied from +0.4 V to +1.3 V at a constant cathodic potential of -1.0 V at a
scan rate of 300 Vs-1. Electrodes were treated with each waveform for 10 minutes at 60
Hz and then 10 minutes at 10 Hz.
2.3.5 Chemical Pre-treatment
CFMs were chemically pretreated with a mixture of H2SO4 (0.25 M) and HNO3
(0.25 M) in a 3:1 ratio38 and washed with DI water prior to analysis.
2.3.6 Solution Geochemistry
Solution chemistry of Cu2+ in tris buffer and NaCl was modeled using
PHREEQCi, a geochemical modeling software capable of determining speciation based
on thermodynamic equilibrium. Stability constants during modeling were based on the
MINTEQ.v4 database developed by the U.S. Environmental Protection Agency while
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additional constants for complexation with solutions were modeled in equilibrium with
CO2(g) (10−4.8 atm.) and O2(g) (10−0.67 atm.).39 The pH values predicted by PHREEQCi
models were found to match the pH observed in experimental solutions.
2.3.7 Fast Scan Controlled-Adsorption Voltammetry (FSCAV)
A CFM was placed into a constantly stirred Cu(NO3)2 solution and a waveform (1.0 V – +1.3 V, resting potential of 0 V, at 600 Vs-1) was applied. An electronic relay
(ADG-419, Analog Devices) was used to switch between the applied waveform and a
constant potential of 0 V for 10 seconds to allow copper adsorption at the electrode
surface reach equilibrium. After 10 seconds, the waveform was reapplied, and the first
background-subtracted cyclic voltammogram was collected and analyzed for total
adsorbed copper. In house LabVIEW 2012 software integrated the reduction peak from
the background subtracted cyclic voltammogram of Cu2+ and Faraday’s law was used to
convert this to a surface concentration (ΓCu). Measured data was fit to the linearized
Langmuir isotherm (eq. 1) where C is the [Cu2+] in bulk solution, Γmax is the maximum
monolayer surface coverage, and K is the equilibrium constant for adsorption. This
experiment was performed in NaCl (10 mM) and tris buffer (15 mM).
𝑐/Γ𝐶𝑢 = Γ

1
𝑀𝑎𝑥

𝑐+Γ

1
𝑀𝑎𝑥 𝐾

(1)

2.3.8 Atomic Force Microscopy (AFM)
CFMs were prepared as described above and electrochemically activated. During
slow scan cyclic voltammograms of Cu(NO3)2 (100 µM) (from +1 V to -1 V , back to +1
V), electrodes were temporarily disconnected for groups of electrodes at 6 different
points. Those were 0.2, -0.6 and -1 V on the forward scan and -0.6, -0.3 and 0.2 V on the
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reverse scan, all vs. Ag/AgCl. These electrodes had been exposed only to a partial section
of the waveform. Electrodes were stored in a closed container and transported to the
AFM. AFM images were taken using a Park Systems XE-NSOM instrument with a noncontact tip.
2.4 Results and Discussion
2.4.1 Slow Scan Cu2+ Cyclic Voltammetry at CFMs
During slow-scan Cu2+ cyclic voltammetry, a cathodic potential sweep is applied
to the electrode at 1 – 10 mVs-1, followed by an anodic sweep that brings the potential
back to rest36. During the cathodic scan, copper is deposited on the electrode surface
following a nucleation and growth mechanism. Copper nucleates over a broad potential
range. These nuclei allow more Cu to deposit during a growth phase at any potential
sufficient for deposition. Therefore, there are often two broad ‘loop’ reduction peaks,
between the same voltages, on both cathodic and anodic scans36. The differences between
the nature of the electrode surface and the Cu surface make this nucleation/growth
deposition occur at a more negative voltage than the standard Cu2+ reduction
potential40,41. Indeed when holding a CFM at a constant potential of 0.34 V (Cu2+ 2e-→
Cu(s) standard reduction potential), addition of Cu(NO3)2 induced no change in current.
This behavior is true for holding potentials down to -0.1 V (data not shown). During the
anodic scan, the deposited Cu(s) is stripped off the electrode surface. Because this happens
from a Cu(s) rich surface (a single phase), the stripping or oxidation peak is sharp and its
voltage is much closer to the standard equilibrium potential40,41. Metal deposition can
also occur via other mechanisms, for example, adsorption, charge transfer, and under
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potential deposition (UPD)42-44. UPD is a process by which a metal deposits onto another
metal at a more positive electrode potential than the Nernst potential for bulk
deposition42.

Figure 2.1. Slow scan cyclic voltammograms of Cu(NO3)2 on (a) AuM and (b) CFM at a
scan rate of 10 mVs-1 in NaCl. Peaks A’ – E’ appear on the AuM, whereas peaks A – D
appear on the CFM.
CFM slow scan cyclic voltammetry of Cu2+ was probed here by comparisons to
AuMs. Figure 2.1 shows representative cyclic voltammograms of Cu(NO3)2 (100 µM) on
a Au Microelectrode (AuM) (a) and a CFM (b) at 10 mVs-1 in NaCl. These two
voltammograms share common features. For example, Cu2+ reduction to metallic Cu
begins at -0.1 V (peaks A’, A) and continues via a loop formation between -0.4 V and 1.0 V on the cathodic scans (peaks B’, B). This loop formation is an indication of
nucleation and growth processes and is similar to previous observations.43 On both AuMs
and CFMs, sharp stripping peaks (C’, C) and shoulder peaks (D’, D) are present between
-0.1 to 0.2 V on the anodic scans.

Shoulders accompanying stripping peaks have

previously been reported on glassy carbon electrodes44 and highly oriented pyrolytic
graphite electrodes43. The presence of complexing agents such as chloride and ammonia
strongly affect copper redox processes and lead to the observation of shoulder peaks at
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potentials higher than stripping peaks41,43-47. Shoulder peaks have not been found to be
associated with stripping peaks in media containing no complexing agents40,48-51.
A mechanism for shoulder peak formation in the presence of Cl- has been
speculated previously44,47,52. First, deposited Cu oxidizes to Cu+, creating a stripping peak
(C’, C) and forming a barely conductive, passive layer of CuCl according to reaction (2).
Cu + Cl- → CuCl + e- -----------------(2)
The CuCl layer shields underlying metallic copper thereby momentarily arresting
further oxidation. Dissolution of this passive layer occurs either via direct diffusion or
diffusion of a more soluble complex (such as CuCl2-). Dissolution exposes the remaining
underlying metal allowing the electro-oxidation of Cu to continue as shown in reactions
(3) and (4):
CuCl + Cl- → CuCl2- ---------------------------(3)
CuCl2-→ Cu2 + + 2Cl- + e- ----------------------(4)
We determined whether these processes are responsible for shoulder peaks D’ and
D by systematically increasing the scan rate as described in the next section. There is an
additional peak on the AuM that is not present on the CFM (peak E’). UPD plays a
significant role in copper deposition on gold surfaces42 whereas on carbon materials,
metallic copper follows bulk deposition with no evidence for UPD41,43,44,46,48,53. Peak E’
on the AuM is likely a consequence of anodic processes associated with UPD on gold42.
2.4.2 Scan Rate Dependence
The shoulder peak mechanism proposed above was tested on CFMs by
progressively increasing scan rate. The rationale here is that by increasing scan rate,
nucleation/growth and hence stripping become limited because these processes are mass-
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transport dependent.41 Because reactions (3) and (4) rely on the stripping peak, any
limitations in stripping should manifest proportionally on the shoulder peak.
In this experiment cyclic voltammograms of Cu(NO3)2 were collected at CFMs at
increasing scan rates. From 10 – 100 mVs-1, raw traces were analyzed; however at higher
scan rates, the charging current due to double layer capacitance dominates the Faradaic
component of the voltammetric signal. Therefore, cyclic voltammograms at 1 Vs -1 and
above were collected in a flow injection system (FIA) using background subtraction.
Figure 2.2 shows cyclic voltammograms collected at 10, 30, 50 and 100 mVs-1
(left, blue panel) and at 1, 50, 100 and 300 Vs-1 (right, green panel). This experiment
illustrates the evolution of a slow scan Cu(NO3)2 cyclic voltammogram in a typical FSCV
signal33. Increased peak separation at high FSCV scan rates is due to slow electron
transfer kinetics. All peaks are labeled as in Figure 2.1. From 10 – 100 mVs-1, the
magnitude of peaks (B) and (C) are greatly reduced such that they are almost absent at
100 mVs-1. This is consistent with the notion that nucleation and growth are masstransport limited and therefore can be ‘outrun’ at high scan rates. The magnitude of peaks
(A) and (D) however are not subject to the same behavior. Peaks (A) and (D) are present
and well defined at 100 mVs-1 implying that these features are neither mass-transport
limited nor dependent on peaks (B) and (C). The results of these experiments indicate
that mechanisms other than those described by Reactions (3) and (4) are responsible for
peak (D).
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Figure 2.2. Left: Slow scan cyclic voltammograms of Cu(NO3)2 on CFMs at scan rates of
10, 30, 50 and 100 mVs-1. Right: Fast scan background-subtracted cyclic voltammograms
of Cu(NO3)2 at scan rates of 1, 50, 100 and 300 Vs-1.
For adsorbed species, the peak current is proportional to scan rate51 and we indeed
found that from 1 – 300 Vs-1, peak amplitudes increased. Furthermore, the slope of a plot
of the log current vs. log scan rate for Cu(NO3)2 was previously reported to be
approximately 1 at high scan rates33. Taken together, these findings strongly support a
hypothesis that peaks (A) and (D) stem from an adsorption controlled process.
Adsorption is explored in the following sections.
2.4.3 CFM Over-oxidation Leads to Enhanced Sensitivity
Activated carbon is widely used in wastewater treatment and is the primary
purification component of domestic water filters54,55. When carbon is activated (e.g. via
heat in the presence of air, or with chemical or electrochemical pretreatments) a wide
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array of oxygen functionalities are created on its surface54. These oxygen moieties adsorb
and complex trace metals, removing them from solution56,57.
CFMs are typically electrochemically pre-treated prior to use56. Therefore, in
analogy to metal adsorption by activated carbon, the oxygen functionalities on the CFM
surface may rapidly complex trace metals in solution, pre-concentrating them on the
surface. In this experiment, we tested the hypothesis that enhanced surface oxidation is
responsible for increased FSCV sensitivity towards Cu2+, presumably due to an increased
number of adsorption sites.

Figure 2.3. Maximum cathodic current of Cu(NO3)2 (10 µM) fast scan cyclic
voltammograms as a function of anodic potential limit (blue series) at 300 Vs-1 and as a
function of acid pretreatment (green).

Using flow injection analysis, we collected background subtracted cyclic
voltammograms of CFMs exposed to a bolus of Cu(NO3)2 (10 µM) with different FSCV
waveforms. We systematically increased the anodic potential limit of the waveform at a
constant cathodic limit, -1.0 V.
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Figure 2.4. (a) Langmuir adsorption isotherms for Cu(NO3)2 on CFMs in NaCl (top) and
in tris buffer (bottom). (b) Histogram showing % [Cu2+]free in solution and % cathodic
current of Cu(NO3)2 (10 µM) in NaCl (purple series) and in tris buffer (black series) at
300 Vs-1 (% cathodic current is shown by setting the maximum cathodic current with tris
buffer to 100% and expressing the cathodic current with NaCl as a percentage of this).
The inset background-subtracted cyclic voltammograms are representative examples
taken in NaCl (purple) and tris buffer (black)

Figure 2.3 shows the magnitude of cathodic current (demonstrated by the inset
cyclic voltammogram) as a function of the anodic potential limit. The cathodic current
showed exponential increases with increasing anodic potential. This exact behavior was
previously reported with neurotransmitters and attributed to surface ‘activation’ or overoxidation56. To confirm that the enhanced sensitivity was due to over-oxidation, an
alternative method to over-oxidize the CFM surface was employed. An acid pretreatment
38

was applied to the electrode surface prior to use (H2SO4 (0.25 M) and HNO3 (0.25 M)

in a 3:1 ratio). An anodic potential limit of +0.6 V was used where we previously found
negligible effects of electrochemical over-oxidation. The resultant cathodic current is
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plotted in green on the 0.6 V series. The current here is substantially higher than the nonacid treated CFM confirming that surface activation, by two separate means, begets
similar outcomes.
2.4.4 Cu2+ Adsorption to CFMs drives the FSCV Signal
We sought to verify that the enhanced FSCV sensitivity towards Cu2+ as a
consequence of activation is an adsorption-driven mechanism. This was successfully
confirmed by construction of adsorption isotherms using fast scan controlled-adsorption
voltammetry (FSCAV) on CFMs57. Adsorption isotherms describe the thermodynamic
equilibrium of Cu2+ onto the CFM, providing an index of the amount of Cu2+ on the CFM
surface with respect to bulk solution via the equilibrium constant, K.
In all experiments described above, we used a simple matrix, NaCl, for
characterizations. The adsorption isotherm of Cu2+ on CFMs in NaCl is shown in Figure
2.4a (top panel) and follows a Langmuir fit. Authentic biological and environmental
matrices are more complicated than NaCl and contain copper binding components.
Therefore, we studied whether a complex matrix would affect Cu2+ adsorption. We
previously characterized copper in tris buffer33 which has considerable metal binding
capacity58,59. Additionally Tris acts as a model biological medium because it contains
amines that mimic proteins. The other salts in the buffer are at a ratio and concentration
designed to mimic artificial cerebrospinal fluid (ACSF). Many neurotransmitters and
other biologically relevant molecules have been characterized in tris in vitro60-62 therefore
adsorption isotherms were additionally constructed in tris buffer, (Figure 2.4a bottom)
also following a Langmuir fit.
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We previously used a geochemical model to calculate the equilibrium
concentrations of free Pb2+ in test solutions32. We employed the same model here to
calculate free Cu2+ concentration ([Cu2+]free) in NaCl and tris solutions. Our isotherms
therefore have two x-axes, (A) denotes the concentration of Cu2+ added ([Cu2+](N)) to the
test solutions and (B) denotes the free Cu2+ concentration [Cu2+]free in solution. For NaCl,
the two x-axes values are similar because NaCl has little Cu2+ binding capacity. Therefore
when calculating K, there is little difference between the values calculated with [Cu 2+](N)
vs. [Cu2+]free (KA and KB). For tris the values of axes (A) and (B) are dramatically
different because tris has Cu2+ binding capacity with K  104 59. It is interesting however,
that when [Cu2+]free is taken into consideration in the calculation, K (KB) is similar to the
K values in NaCl. Therefore, this complex matrix does not affect the monolayer
characteristics of Cu2+ adsorption onto CFMs. This experiment further shows that
solution complexes and other species do not significantly adsorb to the CFM surface and
alter K.
The interactions of the Cu2+- CFM and Cu2+ - tris equilibria are complicated.
Figure 2.4b is a histogram that compares % [Cu2+]free in solution to the cathodic current
of background subtracted cyclic voltammograms of Cu(NO3)2 in NaCl (purple series) and
tris buffer (black series). Shown in the inset are representative examples of cyclic
voltammograms of Cu(NO3)2 in NaCl and tris buffer. In the histogram, we compared the
two FSCV signals thus: the maximum cathodic current with tris buffer was normalized to
100% and the current with NaCl was expressed as a percentage of this. It is seen that
despite only 2% [Cu2+]free in tris buffer, that the Cu2+ signal is 9.2% of the Cu2+ signal in
NaCl (with 98% [Cu2+]free). This discrepancy implies that the two equilibria compete. The
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equilibrium of Cu2+- CFM complexation is more favorable than Cu2+ - tris complexation,
and a serendipitous outcome of this effect is high FSCV sensitivity, even in Cu 2+
complexing matrices.
Given the confirmation that our Cu2+ FSCV signal is highly adsorption driven, the
nucleation characteristics of the cyclic voltammetry peaks on CFMs were next studied.

Figure 2.5. AFM images of a slow scan (10 mVs-1) cyclic voltammogram of Cu(NO3)2
(100 µM) in tris buffer taken at six different points along the scan. On the forward scan,
images were recorded at 0.2 V (i), -0.6 V (ii) and -1 V (iii) and on the backward scan at
0.6 V (iv), -0.3 V (v) and 0.2 V (vi). AFM images are 2 µM x 2 µM.
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2.4.5 AFM Characterization of Cu Nucleation and Oxidation
Changes in the morphology of the CFM surface can be visualized with AFM.
AFM is a sensitive surface imaging technique, which employs a cantilevered tip to
convert surface contours into images.

AFM is routinely used to establish and

characterize the formation of metallic copper on electrode surfaces40,41. In Figure 2.5,
AFM images were recorded at six different points along a slow scan cyclic
voltammogram of Cu(NO3)2 in a complex matrix, tris buffer. Shortly after the start of the
scan (i) the striations of the bare CFM surface are well defined. The small round features
on the surface are likely solid contaminants. At (ii), metallic copper clusters are present
on the CFM surface showing that the eventual cathodic FSCV peak (which evolves from
this peak at high scan rates) involves deposition of Cu(s). Cu(s) is more elaborate during
nucleation (iii) and after growth (iv) where striations are no longer visible under metallic
Cu. After stripping (v), striations are again visible and due to the removal of metallic Cu.
During the stripping process, Cu(s) may either be oxidized to Cu+ (as discussed above) or
directly to Cu2+. The presence of clear carbon striations and the scan rate dependent data
provide little evidence for the formation of CuCl. However, the nature of the peak
directly proceeding the stripping peak (the eventual anodic FSCV anodic peak) is yet to
be determined. One explanation is that this Cu(s) is deposited on specific CFM adsorption
sites that have their own discrete oxidation potentials. The remaining clusters are no
longer present at point (vi), confirming that Cu(s) is completely oxidized at the end of the
scan.
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These surface morphology data confirm the nucleation and oxidation of metallic
Cu associated with the cathodic and anodic FSCV peaks, i.e., peaks A and B in the FSCV
segment of Figure 2.2 are due to Cu2+ + 2 e- → Cu(s) and the reverse reaction.
2.5 Conclusion
FSCV at CFMs is an excellent tool for fast metal analysis with essential
applications in biology and the environment. In this work, we described the fundamental
mechanisms of fast scan voltammetry of Cu2+ on CFMs. In analogy to metal remediation
by activated carbon, we showed that adsorption on CFMs underlies rapid FSCV
responses. We ascertained the thermodynamic and physical characteristics of the CFM
adsorption mechanism. This study has allowed us to understand the fundamentals of
Cu2+ FSCV, enabling future improvements in the sensitivity and selectivity of fast metal
voltammetry for real-time biological and environmental analysis.
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CHAPTER 3
IN VIVO HISTAMINE VOLTAMMETRY IN THE MOUSE
PREMAMMILLARY NUCLEUS

Reproduced with permission from Royal Society of Chemsitry.
Samaranayake S, Abdalla A, Robke R, Wood KM, Zeqja A, Hashemi P (2015) In vivo
histamine voltammetry in the mouse premammillary nucleus. Analyst 140:3759-3765.
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3.1 Abstract
Histamine plays a major role in the mediation of allergic reactions such as
peripheral inflammation. This classical monoamine is also a neurotransmitter involved in
the central nervous system but its roles in this context are poorly understood. Studying
histamine neurotransmission is important due to its implications in many neurological
disorders. The sensitivity, selectivity and high temporal resolution of fast scan cyclic
voltammetry (FSCV) offer many advantages for studying electroactive neurotransmitters.
Histamine has previously been studied with FSCV; however, the lack of a robust
Faradaic electrochemical signal makes it difficult to selectively identify histamine in
complex media, as found in vivo.

In this work, we optimize an electrochemical

waveform that provides a stimulation-locked and unique electrochemical signal towards
histamine. We describe in vitro waveform optimization and a novel in vivo physiological
model for stimulating histamine release in the mouse premamillary nucleus via
stimulation of the medial forebrain bundle. We demonstrate that a robust signal can be
used to effectively identify histamine and characterize its' in vivo kinetics.
3.2 Introduction
The central nervous system holds four aminergic systems, dopamine, serotonin,
norepinephrine and histamine. These messengers are in an intricate chemical interplay
with one-another and other neurotransmitters to precisely modulate many aspects of brain
function. It is critical to understand the fundamental neurochemistry of these four
modulatory systems to better prevent, diagnose and treat brain disorders and diseases.
Fast scan cyclic voltammetry (FSCV) at carbon fiber microelectrodes (CFMs) is a
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uniquely powerful method for in vivo analysis. CFMs are biocompatible, cause negligible
damage to brain tissue and, because of their kinetically favorable surface kinetics,
provide real-time output of electroactive neurotransmitters.
The dopaminergic system has been extensively studied with FSCV over the
previous three decades leading to breakthroughs in understanding dopaminergic
mechanisms in the brain1-3. More recently, FSCV has been recently developed for the
detection of serotonin and norepinephrine4,5 and many important aspects of the two
neurotransmitters are thus being unearthed6-10. Histamine is also an electroactive amine,
and there have been previous reports of histamine induced FSCV signals in mast cells,1113

brain tissue slice preparations14 and in vivo15, however mechanistic studies on

histamine are limited. This is primarily because histamine electrochemistry is complex,
and FSCV induced histamine signals are often interpreted via changes in the capacitative
current on the electrode surface. This approach is fully quantitative, however many
analytes induce a capacitative change at the electrode surface limiting selectivity and
rendering in vivo studies very difficult.
Faradaic electrochemistry more selectively identifies analytes because of the
unique potential position of redox peaks16. In this paper, we discuss the relevance of
histamine adsorption to capacitative currents at CFMs. We describe a novel FSCV
waveform that generates a robust oxidation peak in response to histamine. We show in
vitro, that histamine can be detected selectively and with high sensitivity. Finally, we
report and verify a robust histamine signature in the mouse premamillary nucleus (PM) in
response to medial forebrain bundle (MFB) stimulation.
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Our novel FSCV waveform for histamine provides a tool that will enable the same
level of investigation for histamine as other, more established brain amines. Histamine’s
roles in the brain, in particular with respect to disorders in which it is implicated (e.g.
Alzheimer’s disease) can thus be systematically studied.
3.3 Experimental Section
3.3.1 Chemicals and Reagents
Standard solutions were prepared by dissolving histamine dihydrochloride,
dopamine hydrochloride, serotonin hydrochloride and adenosine hydrocloride (SigmaAldrich, Co., MO, USA) respectively in Tris-buffer. Tris-buffer was constituted thus: 15
mM H2NC(CH2)(OH)3.HCl, 140 mM NaCl, 3.25 mM KCl, 1.2 mM CaCl2, 1.25 mM
NaH2PO4.H2O, 1.2 mM MgCl2 and 2.0 mM Na2SO4 at pH=7.4 in deinoized water (EMD
Chemicals Inc. NJ, USA).
3.3.2 Carbon-Fiber Microelectrodes (CFMs)
CFMs

were fabricated with

7µm

diameter carbon-fibers (Goodfellow

Corporation, PA, USA) aspirated in to glass capillaries (0.6 mm external diameter, 0.4
mm internal diameter, A-M systems, Inc., Sequim, WA). A carbon-glass seal was formed
via a vertical micropipette puller (Narishige Group, Tokyo, Japan). The exposed length of
the carbon fiber was trimmed to 150 µm under an optical microscope. Microelectrodes
were electroplated with Nafion as described previously4.
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3.3.3 Data Collection/Analysis
Waveform generation was via a PCIe-6341 DAC/ADC card (National
Instruments, Austin, TX). Output current was measured by a CHEM-CLAMP
potentiostat (Dagan corporation, MN). Custom built software was employed to drive the
hardware, collect data and perform analysis including background subtraction, signal
averaging and digital filtering (Knowmad Technologies LLC, Tucson, AZ). All potentials
are quoted with respect to Ag/AgCl reference electrodes, which were fabricated via
electrodeposition of Cl- by holding a silver wire (A-M systems, WA) at 4.0 V for 5 s in 1
M HCl. All data represented with error bars represent the standard error of the mean
(SEM). Statistical differences were determined using one-tailed student’s-tests on paired
data sets (p<0.45 was taken as statistically different).
3.3.4 Langmuir Adsorption Isotherms
A CFM was placed into histamine solution of standard concentration and an
optimized histamine waveform was applied. An electronic relay (ADG-419, Analog
Devices) was used to switch between the applied waveform and a constant potential (-0.5
V) for 10 seconds to allow histamine adsorption at the electrode surface and reach
equilibrium. After 10 seconds, the waveform was reapplied, and the first backgroundsubtracted cyclic voltammogram was collected and analyzed for total adsorbed histamine.
In house LabVIEW 2012 software integrated the oxidation peak from the background
subtracted cyclic voltammogram and Faraday's law was used to convert this to a surface
concentration (Γhistamine). Measured data was fit to a linearized Langmuir adsorption
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isotherm as previously described17, and K is the equilibrium constant for adsorption. This
experiment was performed in tris buffer (15 mM).
3.3.5 Flow Injection Analysis
In vitro analyses were performed with flow injection analysis (FIA). CFMs were
inserted into a flangeless short 1/8 nut (PEEK P-335, IDEX, Middleboro, MA) such that
around 2 mm of the tip remained exposed outside of the nut. The microelectrodecontaining nut was then fastened into a modified HPLC union (Elbow PEEK 3432,
IDEX, Middleboro, MA). The other end of the elbow union was fastened into the outflowing steam of the FIA buffer and two holes were drilled into the union for
incorporation of the reference electrode and for a ‘waste’ flow stream. Flow was
maintained with a syringe infusion pump (kd Scientific, model KDS-410, Holliston, MA)
at 2 mL min-1. A rectangular pulse of analyte was introduced into the flow steam for 10 s
via a six-port HPLC loop injector (Rheodyne model 7010 valve, VICI, Houston, TX). For
calibrations and waveform optimization, analytes were injected in random concentrations
order to avoid carry-over effects.
3.3.6 Potentiometry
The open circuit potential between CFMs and Ag/AgCl was measured using a
potentiostat with an integrated high impedance amplifier (eDAQ Pty Ltd, NSW,
Australia). 200 µM of histamine was injected onto the CFM in Tris-buffer using FIA at
pH = 7.4. Subsequent injections were after potential recovered to base line.
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3.3.7 Animal Surgeries
Handling and surgery on male C57BL/6J mice weighing 20−25 g (Jackson
Laboratory, Bar Harbor, ME) were in agreement with The Guide for the Care and Use of
Laboratory Animals, approved by the Institutional Animal Care and Use. Urethane (25%
dissolved in 0.9% NaCl solution, Hospira, Lake Forest, IL) was administered via
intraperitoneal (i.p.) injection, and stereotaxic surgery (David Kopf Instruments, Tujunga,
CA) was performed. A heating pad sustained mouse body temperature around 37 °C
(Braintree Scientiﬁc, Braintree, MA). Stereotaxic coordinates were taken in reference to
bregma. A Naﬁon modiﬁed CFM was inserted into the PM (AP: −2.45, ML: +0.50, DV:
−5.45 to −5.55.). A stainless steel stimulating electrode (diameter: 0.2 mm, Plastics One,
Roanoke, VA) was positioned into the MFB (AP: -1.07, ML: +1.10, DV: −5.00). 120
biphasic pulses were applied through a linear constant current stimulus isolator (NL800A,
Neurolog, Medical Systems Corp., Great Neck, NY). The 60 Hz trains were 350 μA each
phase, 2 ms in width, and 2 s in length. An Ag/AgCl reference electrode was implanted
into the brain’s opposite hemisphere.
3.3.8 Drugs
Tacrine hydrochloride (2 mg kg-1) and thioperamide maleate (20 mg kg-1) from
TOCRIS bioscience (Bristol, UK) were dissolved in saline respectively and injected i.p.
at a volume of 0.6 ml kg-1.
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3.4 Results and Discussion
3.4.1 Histamine Adsorption onto CFMs Underlies Capacitative FSCV Current
Histamine has previously been detected in mast cells and neural tissues with
FSCV11-15. In the majority of these studies, the oxidation peak that appeared at or after
the switching potential on the positive wave, as illustrated in Figure 3.1, was used for
quantification. Figure 3.1Ai is an FSCV color plot during flow injection of histamine (20
µM) onto a CFM with a serotonin sensitive waveform18. The interpretation of color plots
is described in detail elsewhere19, briefly, potential is displayed on the y-axis, time on the
x-axis and current in false color and injection time is denoted by the star.
ii

i
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10 µM [Adenosine]

0.2 V
- 0.1 V

0.2 V
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A
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0.9
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Figure 3.1. A shows color plots for FIA of (i) 20 µM histamine (ii) 10 µM adenosine. B
shows CVs extracted from the vertical dashed lines from (i) and (ii).
A cyclic voltammogram (CV) taken from the vertical white dashed line of the
color plot displays an oxidation peak at around 0.8 V that appears after the switching
potential (on the returning positive scan). In previous work, a stimulation-locked signal in
the rat substantia nigra (SNr) displayed a similar CV and was pharmacologically
determined to be histamine15. In the absence of pharmacology however, it is not possible
48

to selectively verify histamine with this waveform, this is because other electroactive
species give identical CVs. Figure 3.1Aii is a color plot taken during FIA of adenosine
(10 µM). The corresponding CV (Figure 3.1B) is almost identical to that of histamine’s.
In a region containing both adenosine and histamine, therefore, it is not possible to
distinguish between these analytes electrochemically. Furthermore, other work has shown
similar CVs for H2O2 and gonatropin-releasing hormone20,21, further complicating
selective histamine detection.
Histamine electrochemistry is kinetically limited within the oxidation potential
window of previously utilized waveforms. In fact the electrochemical oxidation scheme
for histamine is not known, presumably because it involves charge transfer. We therefore
postulate that the peaks observed in Figure 3.1 are due to non-Faradaic processes. These
processes arise on the CFM surface when spontaneous adsorption of histamine causes
changes in the electrical bilayer. The electrical bilayer on electrode surfaces acts as a
capacitor, discharging current into the electrode, particularly at switching potentials.
Capacitative or charging currents are a well-known phenomenon in FSCV because of the
high scan rates employed16. FSCV is background-subtracted, specifically to remove such
background charging currents which do not reflect Faradaic processes associated with
analytes of interest. However, adsorption of histamine changes the background
capacitative current which cannot be subtracted out, this effect manifests as the features
in the CVs in Figure 3.1.
In Figure 3.2, FIA was utilized to inject histamine (200 µM) onto CFMs while
the open field potential was measured vs. Ag/AgCl (Figure 3.2A). Figure 3.2B shows
that the potential of the CFMs rapidly peaks in response to histamine injections. Because
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there is no driving potential, this implies that histamine spontaneously adsorbs to and
changes the potential of the CFM. The features on histamine’s CV in Figure 3.1 are
likely a consequence of the current that arises from this adsorption. To further verify this
histamine adsorption, Langmuir isotherms were constructed for histamine with a
previously described method22 confirming monolayer coverage of the CFM (Figure
3.2C).
While charging current peaks can quantify histamine, little selectivity is offered
since many analytes adsorb onto CFMs. We therefore designed a novel waveform to
capture histamine electrochemistry before the switching potential.
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Figure 3.2. A shows the schematic diagram of the experimental setup used for
potentiometric experiments. B shows the experimental potentiometric data for five
consecutive injections of histamine (200 µM) on CFM. C Langmuir isotherm for
histamine adsorption on CFMs in Tris buffer.
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3.4.2 Histamine Selective Waveform (HSW)
Histamine contains an imidazole ring and an aliphatic amine group. This
molecule’s ability to readily bind metals such as Cu23,24, because of its electronegative
sites, means that it is readily amenable to oxidation. However histamine electro-oxidation
differs from serotonin and dopamine in that it likely involves charge transfer. This
mechanism introduces kinetic limitations that have not yet enabled stimulation-locked
peaks on the positive direction of the wave in FSCV studies. Therefore preliminary we
utilized a triangular waveform and expanded the potential window to cover a large range
thereby allowing histamine oxidation to occur within a single scan. Through trial and
error we determined that, in vitro, a waveform scanning from -0.7 to 1.1 V (resting at -0.7
V at 600 Vs-1) provided an oxidation peak during the positive scan. However this
waveform was not successful in vivo, showing rapid degradation (fouling). By changing
the resting potential to -0.5 V, we found that electrode degradation was eliminated and in
vivo detection was possible. A possible explanation for this phenomenon is that at -0.7 V,
fouling species (e.g proteins) may preferentially adsorb onto the electrode surface.
Our optimized waveform, the histamine selective waveform (HSW), therefore is 0.7 V to 1.1 V, resting at -0.5 V, with a scan rate of 600 Vs-1. Figure 3.3 compares
histamine detection with the previously described serotonin waveform15 to the HSW.
Figure 3.3A (serotonin waveform) and C (HSW) show color plots and CVs during FIA
of histamine (20 µM). The HSW detects histamine oxidation at around

+0.3 V vs.

Ag/AgCl, and in contrast to the serotonin waveform, this peak occurs before the
switching potential on the positive wave. Furthermore, current vs. time traces, extracted
from horizontal dashed lines from the color plots (Figure 3.3B), show that the HSW
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response is a square injection while the serotonin waveform response does not reach
steady state. This makes it possible to more accurately describe histamine in vivo kinetics
(i.e. histamine clearance kinetics) with the HSW. The HSW has a linear dynamic range
up to 20 µM of histamine (Figure 3.3Dii), a sensitivity of 0.354 ± 0.032 nA/µM and a
limit of detection of 1 µM. Finally, histamine measurements with this waveform show
good stability, as evidenced by the negligible loss in signal (normalized oxidation
current) during 50 successive flow injections of histamine (10 µM) (Figure 3.3E).
3.4.3 HSW Selectivity
We sought to develop a waveform to produce a histamine oxidation peak before
the switching potential on the positive scan to increase the selectivity of FSCV towards
histamine. To assess the selectivity of the waveform in vitro, we tested dopamine,
serotonin and adenosine, which are electroactive species that are chemically similar to
histamine and commonly found in brain regions containing histamine25,26,27. Figure 3.4
shows CVs obtained during FIA of histamine (20 µM), dopamine (100 nM), serotonin
(10 nM) and adenosine (1 µM). These concentrations were chosen to mimic previously
reported evoked in vivo concentrations11,26,28. Adenosine’s peak still occurs at the
switching potential with this waveform and is therefore unlikely to interfere. The
oxidation peak for histamine appears at around 0.3 V vs. Ag/AgCl (green dashed line)
and is in a different position from dopamine and serotonin oxidation peaks (around 0.5
and 0.6 V vs. Ag/AgCl (red and blue dashed lines), respectively).
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Figure 3.3. A & C show color plots for FIA of 20 µM histamine with the serotonin and
HSW waveforms respectively. CVs extracted from vertical dashed lines are shown on the
right. B shows Current vs. time traces from the horizontal dashed lines from color plots.
D shows (i) Calibration curve, (ii) Linear dynamic range (n=4 ± SEM). E Stability of
CFM over 50 consecutive injections of 10 μM histamine (n=4 ± SEM).
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Figure 3.4. CVs for 20 µM histamine, 100 nM dopamine, 10 nM serotonin and 1 µM
adenosine with in vitro FIA using HSW on CFMs. Vertical dashed lines indicate potential
positions of peaks.
The HSW therefore shows good selectivity in vitro. However, the in vivo matrix
is far more complicated than can be reproduced on the bench. We next assessed the
ability of our novel waveform to measure histamine in vivo.
In Vivo Histamine
Histamine and serotonin were previously found to be co-released in the SNr upon
electrical stimulation of the MFB15. We were interested in isolating a histamine signal in
a novel physiological circuitry involving the histamine cell bodies. Histamine cell bodies
are confined to the posterior hypothalamus, the tuberomamillary nucleus (PM), and send
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their afferents to the forebrain via the MFB29,30,31. By utilizing a retrograde-stimulation15
of the MFB, we reasoned that we would be able to detect histamine in the PM since
histamine has previously been measured in this region with microdialysis32.
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Figure 3.5. A shows a representative colors plot of in the PM upon MFB stimulation. B
C
shows a representative in vitro color plot of histamine (20 µM) using FIA. C shows
[histamine] vs. time extracted from the horizontal dashed line from color plot A. D shows
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would be impossible to disentangle histamine’s electrochemistry from this other
electrochemisty occurring at the switching potential.
Figure 3.5C shows how histamine changes with time, determined by extracting
current vs. time from the horizontal dashed line of the color plot and the calibration curve
in Figure 3.3D. Histamine levels elevate in response to electrical stimulation to around 8
µM and then clear after the stimulation, similar in magnitude to histamine release from
mast cells11. This profile is similar to dopamine and serotonin reuptake10,33. This is an
important finding since it implies a similar reuptake system for histamine, however a
histamine transporter is yet to be identified34.
Although the electrochemistry is supportive of histamine’s identity. It is necessary
to perform pharmacological experiments to validate the histamine response. Histamine
neuropharmacology is not well explored in voltammetry models and there are very few
histamine selective compounds that can cross the blood brain barrier. As a first step, we
utilized tacrine, a pharmaceutical therapy for Alzheimer’s disease. Tacrine is thought to
primarily inhibit acetylcholinesterase, however it also is a potent inhibitor of histamine
N-methyltransferase (HNMT) (histamine metabolizing enzyme)35-37. Figure 3.6 shows
the effect on the evoked PM signal (schematic of circuitry shown in Figure 3.6A) upon
i.p. tacrine (2 mg kg-1)38 administration (n=5 animals ± SEM). Consistent with tactrine’s
pharmacokinetic profile in rodents39, there was a clear effect 50 minutes after
administration, whereby the t1/2 of histamine clearance increased significantly from 10.9 ±
1.1 s to 15.44 ± 2.6 s (p=0.01) (Figure 3.6B). This is an expected result of inhibition of
histamine metabolism: because HNMT is located intracellularly40,41, inhibition of this
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enzyme raises cystolic histamine levels which slows down the reuptake equilibria back
into the cell.
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Figure 3.6. A shows the positions of electrodes (stimulation and CFM) in mouse brain. B
& D show representative color plots of stimulated release of histamine using HSW before and after tacrine (2 mg Kg-1) and thioperamide (20 mg Kg-1). C & E show
concentration vs. time traces extracted from horizontal dashed line from B & D
respectively, (n=5 ± SEM). The 2 s stimulation starting at 5 s is shown by the blue bar.
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Because tacrine is non-selective, we performed a further pharmacological
experiment to verify the PM signal. Thioperamide is a selective H3 receptor antagonist.
We would expect thioperamide administration to affect the kinetics of histamine release
and clearance via inhibition of these histamine autoreceptors in the PM42. Figure 3.6C
and D show that 50 minutes after thioperamide (20 mg kg-1)43, there was a pronounced
increase in histamine release from 7.9 ± 2.1 to 11.8 ± 4.6 μM (p=0.02). Increases in
evoked release have previously been seen with dopamine and autoreceptor
antagonism44,45. A significant increase in the t1/2 of histamine clearance was also observed
from 13.3 ± 3.4 s to 18.8 ± 3.2 s (p=0.03), which was seen in prior studies with serotonin
autoreceptor antagonism10. The time course of this experiment is also consistent with
thioperamide’s pharmacokinetics in rodents46. These pharmacological experiments, in
addition to the electrochemical characterization allow us to confidently verify the
histamine nature of this signal in the PM.
3.5 Conclusion
Histamine has important, but not well studied roles as a neurotransmitter.
FSCV is an ideal tool for histamine detection because of its sensitivity, selectivity
and high temporal resolution. Previous FSCV studies have not been able to
selectively identify histamine because the CV features were due to capacitative
processes on the electrode surface that are not selective. Here, we developed the
HSW that provides a robust oxidation peak before the switching peak. We described
in vitro waveform optimization and a novel in vivo physiological model for
retrograde stimulation of histamine release in the mouse PM. We verified this signal
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pharmacologically as histamine. This novel FSCV method will enable detailed in
vivo characterizations of this important neuromodulator.
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CHAPTER 4
A VOLTAMMETRIC AND MATHEMATICAL ANALYSIS OF
HISTAMINERGIC MODULATION OF SEROTONIN IN THE MOUSE
HYPOTHALAMUS

Reprinted with permission from Journal of Neurochemistry and John Wiley and Sons.
Samaranayake S, Abdalla A, Robke R, Nijhout HF, Reed MC, Best J, Hashemi P (2016)
A voltammetric and mathematical analysis of histaminergic modulation of serotonin in
the mouse hypothalamus. J Neurochem 138:374-383.
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4.1 Abstract
Histamine and serotonin are neuromodulators which facilitate numerous, diverse
neurological functions. Being co-localized in many brain regions, these two
neurotransmitters are thought to modulate one another’s chemistry and are often
implicated in the etiology of disease. Thus, it is desirable to interpret the in
vivo chemistry underlying neurotransmission of these two molecules to better define their
roles in health and disease. In this work, we describe a voltammetric approach to
monitoring serotonin and histamine simultaneously in real time. Via electrical stimulation
of the axonal bundles in the medial forebrain bundle, histamine was evoked in the mouse
premammillary nucleus. We found that histamine release was accompanied by a rapid,
potent inhibition of serotonin in a concentration dependent manner. We developed
mathematical models to capture the experimental time courses of histamine and
serotonin, which necessitated incorporation of an inhibitory receptor on serotonin
neurons. We employed pharmacological experiments to verify that this serotonin
inhibition was mediated by H3 receptors. Our novel approach provides fundamental
mechanistic insights that can be used to examine the full extent of interconnectivity
between histamine and serotonin in brain.
4.2 Introduction
Serotonin and histamine are neuromodulators thought to carry a variety of roles in
the brain

1-3

. These two modulators are co-localized in many brain regions

postulated to closely modulate one another

6,7

and are

. However, while there is much focus on

serotonin’s roles in affective, sleep and cognition processes
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4,5

8,9

, histamine’s contribution

to the same processes remains relatively neglected. In recent years, we established fast
scan cyclic voltammetry (FSCV) at carbon fiber microelectrodes (CFMs) to investigate in
vivo serotonin dynamics 10. We are systematically studying the array of in vivo processes
that regulate serotonin extracellular levels

11,12

with the ultimate goal of identifying

distinct mechanistic abnormalities that underlie different pathophysiological states.
Because

of

histamine’s

close

association

with

serotonin,

in

particular

the

electrophysiological, histological and slice voltammetry studies that imply histamine
inhibits serotonin release

6,13-15

we now find it of great importance to direct our efforts to

voltammetrically defining histamine and serotonin co-modulation in vivo.
In this paper, we extend on recent work where we described the first
voltammetrically selective waveform for real time FSCV histamine measurements in vivo
in the mouse 16, to detail simultaneous in vivo measurements of serotonin and histamine.
To achieve this, CFMs were implanted in the mouse premammillary nucleus (PM), a
hypothalamic region rich in serotonin and histamine

4,5,17

. To assess the effects of

histamine release on endogenous serotonin chemistry, we identified a discrete location in
the medial forebrain bundle (MFB) that, when electrically stimulated, evoked histamine
but not serotonin in the PM. This robust experimental model allowed us to observe
histamine release rapidly followed by potent, long lasting serotonin inhibition. We found
that both histamine release and serotonin inhibition were dependent on stimulation
parameters in a manner that indicated an inversely correlative relationship. We
mathematically modeled both responses and found that an inhibitory receptor term was
necessary to fit both sets of data. We postulated that this inhibitory receptor was the H3
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receptor and provided pharmacological evidence, in the form of manipulations with
thioperamide, an H3 receptor antagonist, in favor of our hypothesis.
We thus provide not only an important technological advance, but our
physiological findings also represent an opportunity to more closely scrutinize
histamine’s roles in controlling serotonin chemistry in the context of disease.
4.3 Materials and Methods
4.3.1 Chemicals and Reagents
Standard solutions were prepared by dissolving histamine dihydrochloride and
serotonin hydrochloride (Sigma-Aldrich, Co., MO, USA) respectively in Tris-buffer.
Tris-buffer was constituted thus: 15 mM H2NC(CH2OH)2.HCl, 140 mM NaCl, 3.25 mM
KCl, 1.2 mM CaCl2, 1.25 mM NaH2PO4.H2O, 1.2 mM MgCl2 and 2.0 mM Na2SO4
(EMD Chemicals Inc. NJ, USA) in deinoized water at pH=7.4 Thioperamide maleate (2,
20, or 200 mg kg-1) from TOCRIS bioscience (Bristol, UK) was dissolved in sterile saline
and administered via intra-peritoneal injection at a volume of 0.6 ml kg-1.
4.3.2 Carbon-Fiber Microelectrodes (CFMs)
CFMs were fabricated employing 7µm diameter carbon-fibers (Goodfellow
Corporation, PA, USA) aspirated into glass capillaries (0.6 mm external diameter, 0.4
mm internal diameter, A-M systems, Inc., Sequim, WA). A carbon-glass seal was formed
using vertical micropipette puller (Narishige Group, Tokyo, Japan). The exposed length
of the carbon fiber was trimmed to 150 µm under an optical microscope. Microelectrodes
were electroplated with Nafion as described previously
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10

.

4.3.3 Data Collection
Waveform generation, data acquisition and signal processing were achieved by a
commercial potentiostat (Dagan corp.), custom-built hardware, software written in house
using LabVIEW 2009 and interfacing a PCIe-6341 DAC/ADC card (National
Instruments, Austin, TX). Custom built software was employed to drive the hardware and
perform data analysis including background subtraction, signal averaging and digital
filtering (Knowmad Technologies LLC, Tucson, AZ). All potentials are quoted with
respect to Ag/AgCl reference electrodes, which were fabricated via electrodeposition of
Cl- by holding a silver wire (A-M systems, WA) at 4.0 V for 5 s in 1 M HCl. All data
represented with error bars represent the standard error of the mean (SEM).
4.3.4 Data Analysis
All the Current vs time data were extracted from custom made software.
Histamine current was transferred to its concentration using 2.825 µM/nA factor.
Conversion factor for serotonin was 11 nM/nA. Statistical differences were obtained
using one-tailed Student’s t-tests on paired data sets. (p < 0.05 was taken as significantly
different)
4.3.5 Data Modeling
Simulations were carried out in MatLab R2014a (MathWorks, Natick, MA, USA)
using ODE solver ode23s, implemented on an iMAC with operating system OS X
Version 10.6.8. We modeled our experimental data with two differential equations:
d [eha]
 AH 3 (t ) fireha (t )[vha]  Vu ([eha])  a1[cha]  Vug ([eha])  a2 [ gha] --------- (1)
dt
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The left hand side is the rate of change of the extracellular histamine [eha]. The first term
on the right side multiplies the fractional release, AH3 (t), caused by autoreceptor
inhibition by the firing rate, fireha (t), and the vesicular histamine concentration, [υha].
The remaining terms are reuptake into the terminal, Vu ([eha]), leakage from the terminal,
a1 [cha], uptake into glial cells, Vug ([eha]), and leakage from the glial cells,
a2 [gha]. There is a similar differential equation for serotonin in the extracellular space:
d [e5ht ]
 AH5 ht3 (t ) fire5 ht (t )[v5ht ]  Vsert ([e5ht ])  a3[c5ht ]  Vug ([e5ht ])  a4 [ g 5ht ] ------(2)
dt

The term A5ht
H3 is the time course of fractional serotonin release caused by the H3 receptors
on serotonin neurons. All other terms in equation 2 are analogous to the terms in equation
1.
4.3.6 Flow Injection Analysis
Flow injection analysis (FIA) was used for in vitro analyses. CFMs were inserted
into a flangeless short 1/8 nut (PEEK P-335, IDEX, Middleboro, MA) in order for 2 mm
of the tip to be exposed outside of the nut. The microelectrode-containing nut was then
fastened into a modified HPLC union elbow (PEEK 3432, IDEX, Middleboro, MA). The
other end of the elbow union was fastened into the out-flowing stream of the FIA buffer
and incorporation of the reference electrode and for a ‘waste’ flow stream by drilling into
the union. In vitro experiments were carried out at 2 mL min-1 flow rate using syringe
infusion pump (kd Scientific, model KDS-410, Holliston, MA). Starting at 5s, a
rectangular pulse of analyte was introduced into the buffer stream for 10 s via a six-port
HPLC loop injector (Rheodyne model 7010 valve, VICI, Houston, TX). In order to avoid
carry-over effects, analytes were injected randomly.
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4.3.7 Animal Surgeries
Handling and surgery on male C57BL/6J mice weighing 20−25 g (Jackson
Laboratory, Bar Harbor, ME) were in agreement with University of South Carolina Guide
for the Care and Use of Laboratory Animals, approved by the Institutional Animal Care
and Use. Urethane (25% dissolved in 0.9% NaCl solution, Hospira, Lake Forest, IL) was
injected intraperitoneally (i.p) and once deep anesthesia was confirmed, animals were
secured into a stereotaxic instrument (David Kopf Instruments, Tujunga, CA) and
stereotaxic surgery was performed. A heating pad sustained mouse body temperature
around 37 °C (Braintree Scientiﬁc, Braintree, MA). Stereotaxic coordinates were taken in
reference to bregma. A Naﬁon modiﬁed CFM was in the PM (AP: −2.45, ML: +0.50,
DV: −5.45 to −5.55.). A stainless steel stimulating electrode (diameter: 0.2 mm, Plastics
One, Roanoke, VA) was positioned into the MFB (AP: -1.07, ML: +1.10, DV: −5.00).
Biphasic pulse trains applied through a linear constant current stimulus isolator
(NL800A, Neurolog, Medical Systems Corp., Great Neck, NY) provoked histamine
eﬄux. The 60 Hz trains were 350 μA each phase, 2 ms in width, and 2 s in length. To
determine the effects of different stimulation parameters on histamine and serotonin,
stimulation frequency, width and amplitude were systematically altered. The time in
between stimulations (2 minutes) was determined sufficient to produce negligible effects
on serotonin and histamine in subsequent stimulations. A Ag/AgCl reference electrode
(constructed by plating Cl- ions onto a Ag wire) was implanted into the brain’s opposite
hemisphere.
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4.4 Results
4.4.1 Simultaneous Measurements of Serotonin and Histamine
In this experiment, we implanted a CFM in the PM of an anesthetized mouse and
electrically stimulated the MFB. A representation of this experimental model, illustrating
the relative positions of the working and stimulations electrodes can be found in Figure
4.1Ai. Directly underneath this, in Figure 4.1Bi, is a raw data color plot showing the
resultant electrochemical signal at the CFM. The interpretation of color plots is described
elsewhere in detail 18. Concisely, background subtracted cyclic voltammograms collected
at 10 Hz for 30 seconds are displayed as voltage (y-axis) vs. time (x-axis) and current
(false color). The green bar directly under the color plot denotes the occurrence and
duration of the electrical stimulation. Upon stimulation there are several events, typical of
in vivo FSCV measurements whereby other electroactive species, pH changes and ionic
fluxes affect the measurement

19,20

. Of interest is the discrete event occurring at 0.3 V

which is denoted by the horizontal dashed line and the blue star. A cyclic voltammogram
(CV) extracted from the vertical dashed line through this event is displayed in Figure
4.1Ci (solid line). The oxidation peak at 0.3 V shows excellent agreement with the
oxidation peak extracted from an in vitro injection of histamine (dashed) normalized to
maximum current and superimposed onto this in vivo CV. In our prior work, we showed
electrochemically and pharmacologically that this event is histamine release

16

.

Histamine’s electro-oxidation scheme has not yet been described. It is likely that the peak
at 0.3V occurs because of a proton transfer type oxidation between the aliphatic amine
group and imidazole amine group in the histamine molecule. Because this is an internal
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proton transfer oxidation, it follows that it should occur at a potential lower than observed
for classic serotonin and dopamine electrooxidation (i.e. 0.6 - 0.8 V) 21.
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Figure 4.1. (Ai & Aii) The position of electrodes (stimulation and CFM) in mouse brain.
(Bi & Bii) Representative color plots of the stimulated release of histamine and serotonin
in the premammillary nucleus (PM) and stimulated release of serotonin in the substantia
nigra (SNr) respectively. (Ci & ii) Superimposed cyclic voltammograms of in vivo and in
vitro histamine and serotonin signals taken from vertical dashed lines in the PM. (Ciii)
Comparison of normalized CVs of in vivo serotonin signals taken from vertical dashed
lines in both PM and SNr. HA= histamine, 5-HT = serotonin.

An additional event of interest occurs at around 0.7 V and is denoted by the
horizontal dashed line and red heart. Because FSCV is background subtracted, ambient
levels cannot be determined, thus according to the false color scale, this event signals a
decrease in concentration. A CV collected at the vertical dashed line through this event is
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presented in Figure 4.1Cii. A CV taken from an in vitro injection of serotonin was
inverted on the current axis (to mimic a decrease in concentration), normalized to
maximum current and superimposed (dashed) onto the in vivo CV. The good agreement
between the peaks at 0.7 V strongly implies that this event is caused by serotonin. To
further confirm this notion, we made a measurement of serotonin with this waveform via
an experimental model of MFB stimulation and measurement in the substantia nigra pars
reticulata (SNr) that we have well established for serotonin FSCV

22

. This experimental

model is depicted in Figure 4.1Aii and the color plot arising from the in vivo experiment
is shown in Figure 4.1Bii. The stimulated serotonin event occurs at the same horizontal
(potential) position on the color plot. The CV extracted from this color plot, inverted,
normalized to maximum current and superimposed to the in vivo CV collected in the PM
shows in excellent agreement in Figure 4.1Ciii.
4.4.2 Serotonin Inhibition Following Histamine Release
The event immediately following histamine release proceeds in the negative false
color current direction. FSCV cannot determine basal concentrations (vide supra) thus
one can only determine changes from ambient levels. This result, therefore, is indicative
of a reduction in the ambient concentration of serotonin after stimulation. Figure 4.2A is
a representative color plot showing simultaneous histamine release and serotonin
inhibition in the PM upon MFB stimulation. Figure 4.2C-E shows serotonin and
histamine concentrations with time for different stimulation parameters (dark solid lines
= maximum responses and lighter dashed lines = lower responses) extracted from the
horizontal dashed lines from the color plot (n=5 animals). The decrease in serotonin
concentration is delayed around 2 seconds with respect to histamine release, implying
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that serotonin inhibition may be dependent on histamine release. To probe this notion, we
systematically altered stimulation parameters to assess whether the profile of histamine
release affects serotonin inhibition. The dark solid line shows the maximum responses for
the 60 Hz stimulation frequency in Figure 4.2C.
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Figure 4.2. (A) Representative color plot of the stimulated release of histamine and
serotonin inhibition in the PM. (B) Correlation plot between [histamine] and [serotonin]
for all stimulation parameters. (C) Averaged current vs. time traces along the two
horizontal dashed lines of histamine and serotonin with respect to different stimulation
frequencies (n=5). (D) Averaged current responses to various stimulation pulse widths of
histamine and serotonin (n=5). I Averaged current responses to various stimulation
amplitudes of histamine and serotonin (n=5). [HA] = [histamine], [5-HT] = [serotonin].

The lighter colored dashed lines in Figure 4.2C shows the result of altering the
stimulation frequency from 10 - 40 Hz (n=5 animals). There is a clear correlation
between histamine release and the serotonin inhibition profiles. This is apparent in terms
73

of both time course (i.e. 10 Hz stimulation leading to lower, more prolonged histamine
release and subsequent serotonin inhibition) and amplitude (higher level of histamine
release corresponds to higher level of serotonin inhibition). This pattern holds true for
stimulation pulse width and amplitude (Figure 4.2D and E) (n=5 animals). In Figure
4.2B, the relationship between histamine release and serotonin inhibition was more
formally explored by directly plotting amplitude of histamine release vs. amplitude of
serotonin inhibition for the three stimulation parameters explored. We found a linear
relationship (R2 = 0.757) connecting histamine release to serotonin inhibition for all three
parameters explored.
4.4.3 Mathematical Modeling of Serotonin and Histamine Co-regulation
We needed to vary only three functions, fireha (t), AH3 (t), and A5ht
H3 (t), from
equations 1 and 2 to obtain excellent model fits to our experimental data. Figures 4.3A
and B show the model fits (dotted lines) to the experimental curves (solid lines) for
control and 20 mg kg-1 thioperamide, respectively. Thioperamide selectively acts as an H3
receptor (auto and hetero) antagonist on both histamine and serotonin pre synaptic
neurons

23

. In our model, the electrical stimulation is mimicked by raising fireha (t)

above its tonic level of 5 spikes/sec. Figure 4.3C shows fireha (t) vs. time that best fits
the control and thioperamide experiments. fireha (t) returns to baseline at 9 seconds and
the rates are higher after thioperamide.
To fit the slow decline in histamine after stimulation, it was necessary to
incorporate an autoreceptor function as per our previous serotonin model

12

Figure 4.3D

shows fractional histamine release, AH3 (t), as a function of H3 autoreceptors activation
following stimulation before and after thioperamide. In the control experiment, tonic
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inhibition was AH3 (t)= 0.7 up to 9 seconds, then dropped to AH3 (t)= 0 up to 15 seconds
(complete inhibition), and then returned to AH3 (t)= 0.4 from 15 seconds to 30 seconds.
For thioperamide, AH3 (t)= 0.9, and the smallest fractional release is AH3 (t) = 0.5. Our
model shows that the H3 autoreceptor effect is delayed (starting at 9 seconds) and lasts
throughout our file collection window (30 seconds).
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Figure 4.3. (A) [Histamine] vs. time plots comparing in vivo (solid traces) and the results
of the mathematical model (large dots) in the control case. (B) [Serotonin] vs. time plots
comparing in vivo (solid traces) and the results of the mathematical model (large dots) in
the presence of thioperimide (20 mg kg-1) (C) Firing rate of the histamine neurons as a
function of time in the two cases control (blue) and drug (green), respectively. (D)
Assumed fractional release of histamine from the histamine neurons as a function of time
in the two cases. [HA] = [histamine], [5-HT] = [serotonin].
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We next modeled our serotonin curves. Since the serotonin neurons are not
stimulated, fire5ht (t) remains at a tonic level of 5 spikes/sec. We varied A5ht
H3 (t) (fraction
of serotonin release permitted by the H3 receptors on serotonin neurons). For the control
experiment, A5ht
H3 (t) starts at 0.9, goes down to 0.45, and then returns to 0.9. For
thioperamide, A5ht
H3 (t) starts at 0.9, goes down to 0.36, and then returns to 0.8 at 30
seconds (graphs not shown). As above, the H3 receptor effect is prolonged throughout file
collection (> 60 seconds).
4.4.4 H3 Receptor Mediated Inhibition of Serotonin
Three different doses of thioperamide, an H3 receptor antagonist

23

, were

administered to different groups of mice. This agent’s effects on histamine release and
serotonin inhibition was observed 50 minutes after administration, which is a sufficient
time period for thioperamide to exert its effects 24,25. The results are shown in Figure 4.4.
Here, histamine before drug is displayed in blue and after drug in green, serotonin before
drug is red, and after drug is orange. Error bars showing SEM (n=5 ± SEM) are lighter
versions of these respective colors.
Thioperamide, administered at 2 mg kg-1 caused a significant increase in the
amplitude of histamine release from 7.5 ± 1.4 µM to 11.5 ± 1.4 µM (p = 0.004), but not
in rate of histamine clearance (t1/2 from 11.5 ± 1.5 s to 14.3 ± 2.4 s, p = 0.07). The effects
of 2 mg kg-1 on the amplitude and time course of serotonin inhibition were negligible.
Maximum serotonin inhibition changed from 34.2 ± 7.5 nM to 37.5 ± 11.9 nM (p = 0.55),
whereas, inhibition at 30 s enhanced from 15.8 ± 1.5 nM to 22.1 ± 8.9 nM (p = 0.31).
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Figure 4.4. [Histamine] vs time traces are shown in blue and green for pre and post drug
administration respectively. [Serotonin] vs time traces are shown in red and orange for
before and after the drug. Error bars showing SEM (n=5 ± SEM) are lighter versions of
these respective colors. (A) thioperamide 2 mgKg-1 (B) thioperamide 20 mgKg-1 (C)
thioperamide 50 mgKg-1. [HA] = [histamine], [5-HT] = [serotonin].

Thioperamide administered at 20 mg kg-1 dose affected both the amplitude and
clearance time of histamine response. Histamine elevated from 7.9 ± 2.1 µM to 11.9 ± 4.2
µM (p = 0.03) and t1/2 from 14.7 ± 2.8 s to 19.6 ± 2.3 s (p = 0.02), but only the time
course of the serotonin response (maximum inhibition from 38.8 ± 5.01 nM to 44.8 ± 4.5
nM (p = 0.31). Furthermore, serotonin inhibition at 30 s increases from 16.5 ± 5.3 nM to
37.7 ± 9.6 nM, (p = 0.002). At the highest dose, thioperamide greatly affected histamine
release from 6.8 ± 1.9 µM to 14.3 ± 4.1 µM (p = 0.006) and reuptake such that histamine
does not return to baseline during the 30 second file acquisition window. The effects on
serotonin are also highly significant. Maximum inhibition elevated from 37.3 ± 9.6 nM to
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68.2 ± 20.0 nM (p = 0.04), whereas, inhibition at 30 s enhanced from 24.4 ± 7.9 nM to
65.9 ± 14.8 nM (p = 0.03).
4.5 Discussion
4.5.1 FSCV: A Powerful Tool for Simultaneous, Real-time Serotonin and
Histamine Measurements
FSCV at CFMs is a powerful tool for neurotransmitter analysis because of
FSCV’s rapid, sensitive and selective analysis capabilities in addition to the minimally
invasive dimensions of CFMs. A traditional drawback of FSCV is its limited in vivo
analytical scope (measuring primarily dopamine)

26-28

, which has been systematically

challenged in recent years via advances to measure serotonin 10, adenosine 29, H2O2 30 and
gonadotropin-releasing hormone 31. We are primarily interested in deciphering the in vivo
dynamics that regulate extracellular serotonin levels, and we were thus oriented towards
histamine. There is a significant body of literature that suggests histamine inversely
modulates serotonin in the brain 6,15. Many of these studies propose that dysregulations in
histamine underlie disorders that are primarily considered to be serotonin mediated (e.g.
depression)

32-34

. In 2011 we described simultaneous histamine and serotonin

measurements in the rat SNr 22. However, the FSCV peaks utilized to quantify histamine
occurred at the anodic switching potential. These so called ‘switching peaks’ occur when
spontaneous adsorption of analytes changes the electrical bilayer, hence capacitative
current on the CFM. While switching peaks can be used to quantify histamine in a wellcontrolled environment (i.e. in vitro or tissue slice preparations), they cannot be used in
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vivo because other analytes that adsorb to the CFM provide identical, indistinguishable
CVs 16.
In 2015 we addressed the issue of selective in vivo histamine analysis by
developing a detection waveform that displayed a distinct Faradaic-like peak
corresponding to histamine oxidation. We successfully applied this waveform in vivo to
selectively quantify histamine

16

. In this study, we show that this novel waveform can

simultaneously and selectively measure not only histamine, but also serotonin (vide
infra), which greatly aids our interests in establishing how histamine modulates serotonin
chemistry.
4.5.2 MFB Stimulation Rapidly, Potently Inhibits Ambient Serotonin in the PM
Figure 4.1 shows histamine release upon MFB stimulation in a hypothalamic
region, the PM. We and others previously established this stimulation and measurement
model to be robust and successful in evoking histamine

35,36

since the PM is home to a

dense population of histamine cell bodies 36 and the region of the MFB that we stimulate
contains histamine axons

37,38

. The PM region also contains serotonin terminals

5,17

,

therefore we postulated that the PM seemed a promising area to study
histamine/serotonin modulation, particularly because our data imply that the electrical
stimulation does not evoke serotonin. This finding is supported by the presence of fewer
serotonin axons in the anterior area of the MFB (our stimulation location)

39,40

.

Importantly, this model allows us to investigate histamine’s effects on serotonin
chemistry in the absence of stimulated serotonin release. This type of measurement can
be greatly facilitated in the future with the development of optogenetic tools that
selectively target histamine.
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In accord with our postulation, in Figure 4.1, an event following the evoked
histamine event by around 2 seconds is apparent. Via comparison of CVs collected in
vitro and in vivo in the SNr (an area we have well established for serotonin FSCV)

21,41

,

we can electrochemically verify this second event to be caused by serotonin. The small
deviation in the peak positions in Figure 4.1cii is typical when comparing in vivo and in
vitro responses and is likely due to differences in ohmic drop between in vitro and in vivo
preparations. Of great interest, our data indicate that the serotonin levels are decreasing
in response to the stimulation. Because FSCV is a background subtracted method,
ambient levels cannot be established therefore the conclusion of this data is that MFB
stimulation inhibits ambient serotonin activity by around 40 nM. FSCV most commonly
observes increased neurotransmitter activity, thus our experiment represents an exciting
opportunity to study inhibition of ambient activity.
We next hypothesize that this inhibition is, at least partially, mediated by
histamine based on prior histamine/serotonin modulation studies

6,15

. In the next sections

we take experimental, mathematical and pharmacological approaches towards this
hypothesis.
4.5.3 Histamine Mediates Serotonin Inhibition in the PM
i) Serotonin Inhibition is Concentration and Time Correlated to Histamine Release
To show that histamine, rather than another result of MFB stimulation inhibits
serotonin in the PM, we systematically altered our stimulation parameters to change the
profile of histamine release. Figure 4.2 shows excellent agreement between the time
course and amplitude of histamine release and serotonin inhibition. The raw data in
Figures 4.2 C,D and E show that the profile of serotonin inhibition closely tracks
80

histamine release, and the Figure 4.2B highlights this correlation more formally by
plotting maximum histamine release amplitude vs. maximum serotonin inhibition
amplitude. The linear relationship between histamine and serotonin with all stimulation
parameters is strong evidence for chemical rapport between these two molecules in the
PM.
ii) Mathematical Modeling of Serotonin Inhibition Necessitates an Autoreceptor
Function.
The power of interpreting experimental data through mathematical models is the
ability to test a number of physiological hypotheses. Above, we hypothesized that
serotonin inhibition is histamine mediated, we now test this notion mathematically. Our
model necessitates ambient (basal) histamine and serotonin levels which we are not yet
able to determine with FSCV. For histamine, a value of 1.5 μM was chosen, because our
data show that after stimulation histamine levels fall 1 μM or more below baseline
(Figures 4.2, 3, 4). Similarly, for the same reason we chose 65 nM as the basal
concentration of serotonin in the extracellular space. We found that we could fit the data
closely via simple manipulations of H3 heteroreceptor and autoreceptor strengths in our
model. H3 heteroreceptors on serotonin terminals

15,42

have previously been postulated to

inhibit serotonin 6. Our model supports this hypothesis, particularly given that is unlikely
that the serotonin inhibition we observe is attributable to other slower mechanisms such
as synthesis inhibition. Thus, to probe this idea further, we took a pharmacological
approach.
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iii) H3 receptor Mediation of Serotonin Inhibition
Given the results of our mathematical modeling and the large body of prior work
implicating H3 heteroreceptors as an inhibitory mechanism for serotonin

15,42

we decided

to probe H3 receptor mediation of serotonin. Figure 4.4 shows the results of systemically
administering varying doses of a potent H3 receptor antagonist, thioperamide, to different
mice. The low dose (2 mg kg-1) increased the amplitude of histamine release (consistent
with prior studies with dopamine and D2 autoreceptor antagonism)

43,44

, but has no

significant effect on serotonin. This phenomenon is not difficult to explain because the
serotonin response is controlled by dual mechanisms of a) now increased histamine
available to antagonize H3 receptors and b) a larger percentage of H3 receptors
antagonized on serotonin neurons. The overall result is a manifestation of two opposing
effects that cancel each other out.
The 20 mg kg-1 dose had effects on both histamine release and clearance
(reuptake effects have been previously been seen with serotonin autoreceptor
antagonism) (Wood et al. 2014). The effect on the magnitude of serotonin inhibition was
not significant, however it seems that the prolonged histamine in the synapse is
outcompeting thioperamide for H3 receptors on serotonin neurons to create prolonged
serotonin inhibition (> 60 seconds).
H3 heteroreceptors are likely more localized in the synapse, because of their
position on serotonin terminals

45

than are H3 autoreceptors on presynaptic histamine

neurons. Autoreceptors are generally found outside of the direct synaptic space, asserting
inhibition when a concentration threshold is reached

46

. The inhibition constant (Ki) of

thioperamide is smaller than the Michaelis Menten constant (Km) of histamine towards
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H3 receptors

47,48

. However, after stimulation histamine concentrations are very high in

the direct synaptic space (likely reaching mMs based on prior dopamine models)

49

and

fall off exponentially with distance. Because the thioperamide concentration is assumed
to be homogenous throughout this brain region, the histamine most certainly outcompetes
thioperamide for H3 heteroreceptors on serotonin neurons. This notion is made apparent
by the largest dose (50 mg kg-1) of thioperamide which created significant and long
lasting serotonin inhibition.
In sum, we showcased the power of FSCV for simultaneous measurements of
histamine and serotonin the PM. We showed that MFB stimulation released histamine but
created a potent inhibition of serotonin. Voltammetrically, mathematically and
pharmacologically we showed serotonin inhibition was dependent on histamine release,
via an H3 receptor mediated mechanism. Our approach signals a powerful advancement
in FSCV technology that will facilitate the systematic study of histamine and serotonin
dynamics in the variety of different brain processes involving these two molecules.
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CHAPTER 5
SELECTIVE SEROTONIN REUPTAKE INHIBITORS BLOCK
HISTAMINE REUPTAKE VIA MONOAMINE TRANSPORTERS; A
FAST-SCAN CYCLIC VOLTAMMETRIC STUDY
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5.1 Introduction
Histamine plays many important roles in the brain and irregularities in this
messenger have been implicated in many disorders1-5. Despite this association, the few
central nervous system (CNS) histamine targeting therapeutics show inadequate
efficacy1-3.

This is primarily because little is known about histamine’s roles as a

neuromodulator, other than controlling monoamines via H3 receptors6-8. The relationship
between histamine and serotonin is of particular interest to our lab since we chiefly study
in vivo serotonin regulation mechanisms.
Histamine is released into the synapse via exocytosis and thought to be primarily
enzymatically degraded by histamine N-methyltransferase (HNMT)9-12. While there is
evidence for partial histamine reuptake into synaptosomes13,14 and astrocytes15,16, a
transporter for histamine has not been identified17,18. Given that HNMT has been found to
be exclusively intracellular,19,20 it seems incongruent that there would not exist an active
histamine reuptake mechanism. We therefore sought to clarify this inconsistency.
We recently described a fast-scan cyclic voltammetry (FSCV) technique that can
simultaneously measure in vivo histamine and serotonin with sub-second temporal
resolution at carbon fiber microelectrodes (CFMs). In this paper we investigated
histamine reuptake by dopamine transporters (DATs), serotonin transporters (SERTs),
norepinephrine transporters (NETs) and organic cation transporters (OCTs). The rationale
here originated from our prior work where we mathematically modeled histamine
responses and found that the clearance curve could be fit with first order MichaelisMenten kinetics,14,6 commonly seen for dopamine21 and serotonin22,23 active reuptake.
Additionally, Lyn Daws previously reviewed evidence for ‘promiscuous’ reuptake of
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dopamine, serotonin and norepinephrine between monoamine transporters24. Taken
together, these findings provide a compelling platform for monoamine transporters in
synaptic histamine removal.
By electrically stimulating histamine release in the mouse posterior hypothalamus
(PH) we observe the effects of pharmacological manipulations on the DAT, NET, SERT
and OCTs on histamine reuptake. First, we show the lesion left by the CFM in
histological section for all the experiments, attesting to the high accuracy of our surgical
procedure. Second, the in vivo histamine response is highly reproducible between groups
of animals. Third, vehicle injections do not substantially change control responses.
Fourth, the histamine clearance profile is not altered by DAT inhibition. Fifth,
desipramine-mediated NET inhibition and SERT inhibition via 3 different SSRIs exert
varying degrees of reuptake inhibition on histamine. Despite the heterogeneous response
to these agents, one commonality between them is that they all have the capacity to
inhibit OCTs. Thus, OCTs are blocked, generating the most dramatic decrease in the rate
of histamine reuptake. Collectively, our results suggest an active reuptake mechanism for
histamine, likely primarily via the OCTs. This information is important for improving
development

and

efficacy

of

neuropharmaceuticals

for

histamine

during

pathophysiology.
5.2 Materials and Methods
5.2.1 Pharmacological Agents
Escitalopram oxalate, citalopram hydrobromide, sertraline hydrochloride, GBR
12909 dihydrochloride, desipramine hydrochloride, decynium-22 iodide were ordered
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from Sigma-Aldrich, MO, USA. All drugs were dissolved in 9% sterile saline solutions
and administered via i.p injection at 0.1 20 mL/g except for sertraline and decynium-22,
which were dissolved in DMSO at 5% concentration in sterile saline.
5.2.2 Carbon-Fiber Microelectrodes (CFMs)
Carbon-fibers (Goodfellow Corporation, PA, USA) of 7 µm diameter were
aspirated into glass capillaries (0.6 mm external diameter, 0.4 mm internal diameter, A-M
Systems, Inc., Sequim, WA) to fabricate the CFMs. A carbon-glass seal was formed
using vertical micropipette puller (Narishige Group, Tokyo, Japan). The exposed length
of the carbon-fiber was trimmed to 150 µm under an optical microscope. CFMs were
electroplated with Nafion.
5.2.3 Data Collection
A commercially available potentiostat (Dagan Corporation, Minneapolis, MN)
and custom build hardware interfacing a PCIe-6341 DAC/ADC card (National
Instruments, Austin, TX) were used for waveform generation, data acquisition, and signal
processing. Custom built software, written in-house using LabVIEW 2009, was used to
drive the hardware and perform data analysis including background subtraction, signal
averaging and digital filtering (Knowmad Technologies LLC, Tucson, AZ). All potentials
were measured with respect to Ag/AgCl reference electrode. The reference electrode was
fabricated via electrodeposition of Cl- by holding a silver wire at 5.0 V for 5 s in 1 M
HCl. All the error bars represent the standard error of the mean (SEM).
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5.2.4 Data Analysis
All current vs. time curves and cyclic voltammograms (CVs) were collected with
software made in-house. Current was converted to concentration by using standard
calibration factors, for histamine = 2.82 µM/nA and serotonin = 11 nM/nA. One-tailed
Student’s t-tests on paired data set were used to determine statistical significance (p <
0.05 was taken as significantly different).
5.2.5 Animal Surgeries
Handling and surgery on male C57BL/6J mice weighing 20−25 g (Jackson
Laboratory, Bar Harbor, ME) was in agreement with the University of South Carolina’s
Guide for the Care and Use of Laboratory Animals, approved by the Institutional Animal
Care and Use. Urethane (25% dissolved in 0.9% sterile saline solution, Hospira, Lake
Forest, IL) was injected i.p and once deep anesthesia was confirmed, animals were
secured into a stereotaxic instrument (David Kopf Instruments, Tujunga, CA) and
stereotaxic surgery was performed. A heating pad was used to sustain mouse body
temperature around 37 °C (Braintree Scientiﬁc, Braintree, MA). Stereotaxic coordinates
were taken in reference to bregma. A Naﬁon plated CFM was placed in the PH (AP:
−2.45, ML: +0.50, DV: −5.45 to −5.55.). A stainless-steel stimulating electrode
(diameter: 0.2 mm, Plastics One, Roanoke, VA) was positioned into the MFB (AP: -1.07,
ML: +1.10, DV: −5.00). Biphasic pulse trains were applied through a linear constant
current stimulus isolator (NL800A, Neurolog, Medical Systems Corp., Great Neck, NY)
to provoke histamine eﬄux. The 60 Hz trains were 360 μA each phase, 2 ms in width,
and the stimulation was 2 s in length. All potentials were measured with respect to a
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Ag/AgCl reference electrode (constructed by plating Cl- ions onto an Ag wire) which was
implanted into the opposite brain hemisphere.
5.2.6 Histology
To verify the placement of the CFMs in vivo, after experimentation the CFM was
used to create a small lesion in the recording site by applying a constant potential (20 V
for 10 s)25. Following experiments, mice were sacrificed and brains were removed from
the skull and stored in 10% paraformaldehyde solution in phosphate buffered saline
(PBS). The brains were then stored in 15% sucrose until they sank. Brains were then
flash-frozen, sectioned into 20 µm slices using a cryostat (Cryotome FSE, Thermo
Scientific, Kalamazoo, MI) and mounted on glass slides. Finally, brain slices were
stained with 0.2% crystal violet and photographed under an optical microscope.
5.3 Results and Discussion
5.3.1 Histology
Figure 5.1 shows a representative image showing the lesion of the CFM (A) and
the stimulating electrodes (B) circled in blue. In Figure 5.1C, the location of all the
electrodes utilized in this study (one electrode per mouse) are shown in slices between
Bregma -2.30 to -2.92.
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Figure 5.1. CFMs and stimulating electrode placements in PH and MFB respectively.
(A) CFM lesion which is denoted by a blue circle. (B) Left hemisphere is a diagram
illustrating intended placement of MFB, and right hemisphere shows the actual placement
of the electrode. (C) CFMs placement in PH.
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5.3.2 Selective sub-second neurochemical detection of histamine
Upon electrical stimulation of the MFB, histamine was evoked in the PH and this
was verified with FSCV recording, as visualized in the color plot in Figure 5.2. Figure
5.2A-F shows representative color plots, cyclic voltammograms (CVs) and averaged
[histamine] vs. time responses in groups of animals that served as controls for subsequent
pharmacology experiments (animal groups A to F). The interpretation of color plots is
described elsewhere in detail6,26. Briefly, background subtracted cyclic voltammograms
collected at 10 Hz for 30 seconds are displayed as voltage (y-axis) vs. time (x-axis) and
current (false color scale). The green bar directly underneath the color plot denotes the
occurrence and duration of the electrical stimulation. Upon electrical stimulation, there
are several non- faradaic events, due to other electroactive species, pH changes and ionic
fluxes27,28 which occur at the switching potentials. Distinct histamine oxidation occurs at
0.3 V, denoted by the horizontal dashed line.
CVs for histamine detection for each drug were extracted from each color plot at
the vertical dashed line through the event, which is represented by a yellow star, and
illustrated in middle column of the Figure 5.2 (Cyclic Voltammograms). The oxidation
peak at 0.3 V (blue bar named as histamine) proves the selective histamine detection.
Figure 5.2 right column shows the electrically evoked average histamine responses,
which are extracted from horizontal dashed line named HA from each color plot. This
data shows the high reproducibility between control histamine responses.
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Figure 5.2. The representative color plots, cyclic voltammograms (CVs) and evoked
histamine traces for control experiments in different sets of animal groups 1 to 6. Left
column shows color plots. The middle column illustrates CVs that were extracted from
each color plot at the vertical dashed line (denoted by the yellow star). Right column
shows the average control [histamine] vs time traces for each drug category (n=5 ±
SEM). Shaded region around the trace represents the SEM. Green bars underneath each
color plot and each trace in the right column represent the stimulation. Blue vertical bars
in the middle column highlights the histamine oxidation peak.
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5.3.3 Effect of Vehicle

Figure 5.3. Top panel - [histamine] vs. time traces are shown in blue and green for pre
and post-vehicle administration respectively. Bottom panel - [serotonin] vs. time traces
are shown in red and orange for before and after the vehicle respectively. Error bars
showing SEM (n=5 ± SEM) are lighter versions of these respective colors. (A) 5%
DMSO and (B) Saline
In the proceeding pharmacological manipulations, either 5% DMSO or sterile
saline were used to dissolve active agents. Therefore, DMSO and saline were
administered to different groups of mice to test the effects of vehicle on the signal.
Figure 5.3A shows the average concentration vs. time traces of histamine (top panel), we
also measured serotonin (bottom panel). This inverse serotonin response illustrates the
reduction of ambient serotonin concentration via H3 receptor activation by evoked
histamine, as we previously showed. Histamine and serotonin responses after 50 minutes
of 5% DMSO administration (i.p.) are presented in green and orange traces respectively
and have negligible effects on the signal.
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5.3.4 OCT-mediated histamine uptake: pharmacological evidence

Figure 5.4. Comparison of histamine and serotonin responses after monoamine
transporter inhibitors. (A) GBR 12902 (15 mg/kg) (B) desipramine (15 mg/kg) (C)
escitalopram (10 mg/kg) (D) citalopram (5 mg/kg) I sertraline (10 mg/kg). (F) decynium22 (0.1 mg/kg). In each drug category, average histamine vs. time traces collected every
10 minutes for 60 minutes are shown in 3D plots (left panel). The right panel shows the
[histamine] vs. time traces for control in blue and 50 minutes post-drug in green.
[serotonin] vs. time traces are shown in red and orange for control and post-drug
respectively. Stimulation period is represented by a green bar between histamine and
serotonin responses. Error bars represents the SEM (n=5 ± SEM) in lighter versions of
these respective colors.
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Next, we investigated histamine reuptake via 4 monoamine transporter proteins.
Six different transporter inhibitor drugs, GBR 12902 (15 mg/kg), desipramine (15
mg/kg), escitalopram (10 mg/kg), citalopram (5 mg/kg), sertraline (10 mg/kg) and
decynium-22 (0.1 mg/kg), were injected (i.p.) into different mice. Histamine and
serotonin responses were measured every 10 minutes, for 60 minutes, after drug
administration. Figure 5.4A-left shows a 2D representation of a 3D plot of histamine
responses upon stimulation with time after drug. The first solid black trace in the 3D plot
represents the pre-drug [histamine] response. [Histamine] responses collected every 10
minutes after drug administration, for 60 minutes, are stacked next to one another and
given a false color. The x-axis represents 30 seconds for an individual file, y-axis
represents 60 minutes after the drug administration and z-axis represents [histamine].
This 2D plot allows for visualization of the effects of the time course of an agent’s effects
on histamine reuptake. The right panel in Figure 4A shows averaged histamine traces
before drug (blue) and 50 minutes after the drug (green) and averaged serotonin traces
before drug in red and after drug in orange between animals (n=5 ± SEM). Figure 4B, C,
D, E, and F demonstrate the effects of desipramine (15 mg/kg), escitalopram (10 mg/kg),
citalopram (5 mg/kg), sertraline (10 mg/kg) and decynium-22 (0.1 mg/kg) respectively.
DATs
High levels of histamine decarboxylase have been found in dopamine-rich regions
such as the striatum29. In addition, histamine receptors are heavily expressed in the
nucleus accumbens18,30, an area extensively studied for dopamine transmission31,32. There
is also evidence for histaminergic modulation of dopamine transmission in the striatum
and nucleus accumbens33,34. Given the abundance of physiological evidence for co99

actions of dopamine and histamine, we first tested whether DATs mediate histamine
reuptake. A potent DAT inhibitor, GBR 1290935, did not lead to significant changes in
histamine reuptake as shown in Figure 4A. This observation suggested that there is no
involvement of DAT in histamine reuptake in the PH.
NETs
Recent studies have shown the existence of NETs in rat posterior and anterior
hypothalamic36,37 area as well as the regulation of norepinephrine via H3 receptors38.
Together this evidence suggests possible comodulation of norepinephrine and histamine.
In comparison to DAT, the NET inhibitor, desipramine, slightly decelerated the reuptake
of histamine when compared to control animals (Figure 4B). An interesting finding is
that NET blockage enhanced histamine-mediated serotonin firing inhibition. The
antidepressant-like effects of this tricyclic antidepressant drug suggest the regulation of
serotonergic system through SERTs24,39,40.

Extracellular histamine also plays a

significant role in regulating the serotonin release via H3 receptors. Hence, resulting in
greater inverse regulation of serotonin via H3 activation.
SERTs
We and others have shown that histamine modulates serotonin transmission8,41.
Serotonin is reuptaken with high efficiency by SERTs 42. SERTs are localized in some of
the highest numbers in the PH43,44. Given the close modulatory relationship between
histamine and serotonin, we next decided to study whether SERT inhibition exerts an
effect on histamine clearance. Escitalopram45 and citalopram46 (selective serotonin
reuptake inhibitors (SSRIs)) substantially slowed histamine reuptake and lead to a
decrease in histamine-mediated serotonin inhibition compared to control responses as
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shown in Figure 5.4D & E. However, sertraline47, also an SSRI, had minimal effects on
the histamine signal. Thus, the discrepancy between the three SSRIs proposes that SERT
may not be the primary reuptake mechanism for histamine. Like desipramine,
escitalopram and citalopram both have high affinity for the OCT but sertraline does
not48,49. We thus turned to the OCTs.
A point to note is that SERT inhibitors (escitalopram and citalopram) exhibit
slightly less inhibition of serotonin with respect to controls (Figure 5.4 D & E). The
enhanced release of serotonin by SERT inhibitors45 overcomes the inhibition of serotonin
via H3 receptors6 and makes the inverse modulation of serotonin less but insignificant in
the post-drug condition.
OCTs
We inhibited the OCT reuptake mechanism via decynium-2249 in a final set of
mice. Decynium-22 demonstrated the most significant effect on histamine clearance, as
shown in Figure 4F, suggesting OCT mediated histamine reuptake. Furthermore, postdrug inverse modulation of serotonin illustrated insignificant inhibition when compared
to the control response (Figure 4F). This may be due to the bidirectional effects of
elevated extracellular serotonin by inhibiting the OCT-mediated serotonin uptake48-50 and
the serotonin inhibition via histamine6.
Conclusion
Histamine is a vital monoamine neurotransmitter which plays a significant role in
the brain, but histamine’s reuptake mechanism is less studied. This electrochemical and
pharmacological study demonstrated the implications of monoamine transporters towards
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histamine’s reuptake mechanism. The histamine clearance profile was not affected by
DAT inhibition. Whereas, NET and SERT inhibition demonstrated an inconsistency in
reuptake inhibition on this messenger. Because of the NETs and SERTs inhibitory
agents’ ability to inhibit OCTs, we finally, blocked the OCTs, which in turn showed the
largest decrease in the histamine reuptake rate. Collectively, this work suggests an OCT
mediated histamine reuptake mechanism in the brain. These novel discoveries illustrate
the actions of monoamine transporters on histamine neurodynamics and offer new insight
into histamine targeting therapeutic strategies.
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CHAPTER 6
HISTAMINERGIC MODULATION OF SEROTONIN DURING
DISEASE; THE HIV-1 TG MODEL
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6.1 Introduction
Neuroinflammation is garnering increasing interest for its potential role in the
pathology of many diseases and is commonly marked by increases in biomarkers such as
proinflammatory cytokines1-3. In addition, recent studies have shown elevated brain
histamine levels during neuroinflammation2,4. Neuroinflammation can originate from
infections, brain injuries, viruses like human immune deficiency virus (HIV-1) and many
other neurological disorders. Histamine is a monoamine neurotransmitter that regulates
important brain functions and modulates other neurotransmitters like serotonin5-10. These
monoamine neurotransmitters, including histamine and serotonin, are frequently
implicated in the neurological disorders which are comorbid with neuroinflammation10-12.
The lack of knowledge on the actions of the brain’s chemical messengers during
inflammation seen with certain brain disorders makes the pathology difficult to properly
elucidate.
Neuroinflammation is an important symptom in HIV and in the rat HIV-1 Tg
disease model. Recent studies have shown that HIV-1 Tg rats exhibit elevated levels of
proinflammatory cytokines (INF-γ, TNF-α, and IL-1β), which are key biomarkers of
inflammation13. In addition, the viral protein glycoprotein gp120 binds to the chemokine
receptor, which exists in many of the cells present in the central nervous system,
including neurons14,15. The neurotoxic effects of gp120 include induction of apoptosis
and neural injury16 and can result in neuroinflammation during the adolescent period of
the HIV-1 Tg rat’s life. Therefore, HIV-1 Tg is an excellent animal model to study
neurotransmitter dynamics that accompany low-grade, chronic neuroinflammation.
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This disease model has shown a trend toward increased anxiety-like behavior17,18
as shown by open-field, general locomotor activity, and motivated behavior tests.
Additionally, social interaction, novel stimulus and forced swim tests have revealed that
HIV-1 Tg rats exhibit elevated depressive-like behaviors18. These observations are of
particular interest as serotonin is the transmitter primarily implicated in depression and
anxiety19,20. Given that histamine release is associated with local peripheral inflammation,
and given we find that histamine inversely regulates serotonin in the brain, an important
question follows: Is histamine involved in neuroinflammation and if so, how do
alterations in histamine affect serotonin? We will ask these questions in the HIV-1 Tg rat.
In this study, we employed our dual histamine/serotonin measurement strategy to
investigate histaminergic regulation of serotonin in HIV-1Tg rats. To accomplish this
task, we positioned the carbon fiber microelectrodes (CFMs) in the rat posterior
hypothalamus (PH) and the stimulation electrode in the medial forebrain bundle (MFB).
We found that histamine release was elevated in the disease model resulting in increased
serotonin inhibition. We hypothesized that this elevated histamine would suppress
evoked serotonin release. To test this hypothesis, we positioned another CFM in the
prefrontal cortex (PFC) to investigate the stimulated release of serotonin. HIV-1 Tg rats
were shown to have attenuated serotonin release with respect to control animals. Our
results imply that histamine may play an important role in this regard. Collectively, this
study works toward characterizing the importance of histamine’s role in controlling the
serotonin release during disease states marked by neuroinflammation.
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6.2 Methods
6.2.1 Animals
Male and female F344 rats (n=17) and HIV-1 Tg rats (n=17) (Harlan
Laboratories, Indianapolis, Indiana) were commercially ovariectomized and pair-housed
by genotype. Food and water were provided ad libitum throughout the experiment.
Animals were kept in an AALAC-accredited facility at 21 +/- 2 C, 50% +/- 10% relative
humidity, in a 12-hr light-dark cycle with lights on at 07:00h. All experiments were
performed according to the National Institute of Health guidelines for AAALAC
accredited facilities. All behavioral testing was conducted during the animal’s light
cycle. The research protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of South Carolina, Columbia, SC, under animal
assurance number A3049-01.
6.2.2 Carbon fiber microelectrodes (CFMs)
CFMs were fabricated according to Samaranayake et. al.,21. In brief, 7 umdiameter carbon fibers (Goodfellow Inc, Coraopolis, PA) were aspirated into glass
capillary tubes (OD 0.6 mm, ID 0.4 mm, A-M Systems INC, Sequim, WA). A vertical
pipette puller was used to seal the carbon fiber to the capillary tube (Narishige Group,
Tokyo, Japan). The carbon fiber was then trimmed to 150 µm under a low-power light
microscope. All microelectrodes were nafion-coated as per Hashemi et al., 200922.
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6.2.3 Animal Surgery
Before surgery, animals were anesthetized using 2-3% sevoflurane inhalant
(Abbot Laboratories, North Chicago, IL ). Once the animal was fully anesthetized, it was
placed in the stereotaxic apparatus, and the head was leveled with respect to bregma
(David Kopf Instruments, Tujunga, CA). A heating pad (37 0C) was placed under the
animal throughout the course of the experiment. CFMs were placed to PFC (AP: +2.6,
ML: +0.6, DV: -4.7) and PH (AP: -3.96, ML: +1.8, DV: -8.0 to -8.5) to detect serotonin
and histaminergic regulation of serotonin respectively. A stainless-steel stimulating
electrode (diameter: 0.2 mm, Plastics One, Roanoke, VA) was positioned into the MFB
(for histamine, AP: -1.8, ML: +1.8, DV: −8.0 and for serotonin, AP: -2.40, ML: +1.8,
DV: -8.0). Biphasic pulse trains were applied through a linear constant current stimulus
isolator (NL800A, Neurolog, Medical Systems Corp., Great Neck, NY) to provoked
histamine efflux. The 60 Hz trains were 360 μA each phase, 2 ms in width, and 2 s in
length. All potentials were measured with respect to a Ag/AgCl reference electrode
(constructed by plating Cl- ions onto a Ag wire) which was implanted into the brain’s
opposite hemisphere.
6.2.4 Data Collection
A commercially available potentiostat (Dagan Corporation, Minneapolis, MN)
and a custom built hardware interfacing a PCIe-6341 DAC/ADC card (National
Instruments, Austin, TX) were used to attain waveform generation, data acquisition, and
signal processing. Custom built software, written in-house using LabVIEW 2009, was
used to drive the hardware and perform data analysis including background subtraction,
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signal averaging and digital filtering (Knowmad Technologies LLC, Tucson, AZ). All the
error bars represent the standard error of the mean (SEM).
6.3 Results
6.3.1 Histaminergic Regulation of Serotonin

Figure 7.2. (A & B) Representative color plots of simultaneous detection of evoked
histamine and ambient serotonin in the posterior hypothalamus of control (F344) and
HIV-1 Tg rats respectively. Inset in each color plot (white trace) are CVs taken from the
vertical dashed lines. (C) Top panel - [Histamine] vs. time plots for the control rats (solid
blue trace) and HIV-1 Tg rats (solid red trace). Bottom panel - [Serotonin] vs. time plots
comparing control animal (solid blue trace) and HIV-1 Tg (solid red trace). Shaded
regions in each trace show the standard error of the mean (SEM) for n=7 animals. Green
bars underneath the color plots denote occurrence and duration of the electrical
stimulation (2 s)
In this experiment, we simultaneously detected in vivo histamine and serotonin in
HIV-1 Tg rats. Figure 7.2 illustrates histaminergic regulation of serotonin in the rat PH.
Figure 7.2A & B show representative color plots of simultaneous detection of histamine
and serotonin for control and HIV-1 Tg rats, respectively. Stimulated release of histamine
is enhanced in HIV-1 Tg rats (red) with respect to control animal (blue) as shown in
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Figure 7.2C- top panel. Similarly, inverse regulation of serotonin is also increased in
HIV-1 Tg rats (red) when compared to the control (blue) as shown in Figure 7.2C.
6.3.2 Serotonin
We then positioned the CFM in the prefrontal cortex to detect the stimulated
release of serotonin. Figure 7.2 A & B illustrate representative color plots of evoked
serotonin for control and HIV-1 Tg rats, respectively. Stimulated release of serotonin was
significantly attenuated in HIV-1 Tg rats (red) in comparison to control animals (blue) as
shown in Figure 7.2 C.

Figure 7.3. (A & B) Representative color plots of the stimulated release of serotonin in
the prefrontal cortex of control and HIV-1 Tg rats, respectively. Inset in each color plot
(white trace) shows the typical cyclic voltammogram for serotonin, extracted from the
vertical dashed line along the event. (C) [Serotonin] vs. time plot comparing control
(solid blue trace) and HIV-1 Tg rats (solid red trace). Shaded regions in each trace show
the standard error of the mean (SEM) for n=10 animals. Green bars underneath the color
plots denote the occurrence and duration of the electrical stimulation (2s)
6.4 Discussion
This animal model (HIV-1 Tg rats) expresses seven of the nine genes produced by
the HIV-1 virus in humans and displays the same symptoms occurring after infection in
patients receiving combination antiretroviral therapies23. Replication of the HIV virion is
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dependent on the Pol protein which is not expressed in the HIV-1 Tg rat. Therefore,
while the presence of the virus is maintained in the blood, the virus cannot replicate.
These transgenic rats have been shown to express neurological disorders that mirror HIV
in humans24,25. In addition, this disease model develops cognitive, motor and behavioral
anomalies which may be linked to elevated immune activation26-28. Thus, we can safely
use this model of disease to investigate the histamine and serotonin chemistry underlying
neuroinflammation.
Recent studies of HIV in humans proved that the virus enters the central nervous
system in early stages of the infection through infected macrophages and monocytes29.
Various HIV-1 glycoprotein gp120 isolates interact with the α- or β-chemokine receptors
that exist on macrophages/microglia, astrocytes, and neurons15. These infected cells
secrete THF-α, IL-1β, nitric oxide and quinolinone which are inflammatory markers30.
These

inflammatory

mediators

are

neurotoxic

and

can

potentially lead

to

neuroinflammation. Therefore, apoptosis could occur through direct interaction between
gp120 and neurons or through the release of neurotoxic factors like inflammatory
mediators15.
Microglial cells, the immune cells in the brain, protect the brain from injuries,
viruses and infections. These immune cells migrate to the infected sites and release
inflammatory mediators31. Recent studies have shown that histamine modulates
microglial migration and the release of inflammatory mediators like cytokines32 and nitric
oxide2. Mast cells also contribute to the innate immune system in both central nervous
system and peripheral system33. Mast cells can be found in the brain and these cells
interact with astrocytes, neurons, and microglial cells34,35. The number of mast cells
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present is considerably lower in healthy organisms than in inflammation states. With
inflammation, mast cells migrate through BBB36 and release more inflammatory
mediators like histamine and cytokines37 again suggesting histamine may have a
significant role in brain diseases which are associated with neuroinflammation. Our
results also support the hypothesis, as elevated histamine release was observed in HIV-1
Tg rats when compared to the control animals (Figure 7.1). The recruiting of more mast
cells into the brain during neuroinflammation and the release of more histamine to
regulate microglial cells may possibly result in the elevated stimulated release of
histamine in HIV-1 Tg rats.
Our own and other studies have shown that H3 receptors regulate serotonin
release7,9,38. Therefore, it follows that histamine release during neuroinflammation would
result in enhanced serotonin inhibition. Accordingly, HIV-1 Tg rats demonstrated greater
inhibition of serotonin (Figure 7.1). This observation was also reflected in the stimulated
release of serotonin in PFC (Figure 7.2). Moreover, impaired serotonin levels have been
implicated in many brain disorders like depression and neurodegeneration, which are also
comorbid with neuroinflammation39-42. Collectively, histamine may have a significant
impact in controlling the serotonin release during brain diseases that also exhibit
increased neuroinflammation.
In summary, we have illustrated that our novel electrochemical method can be
used to investigate real-time in vivo histaminergic regulation of serotonin in disease or
pathophysiological states. The fundamental neurochemical information gained from this
study will be vital to revealing histamine’s true role in neurological disorders. More
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pharmacological, animal model, and behavior experiments are necessary to further
establish this hypothesis.
6.5 References
(1)

Cacabelos, R.; Torrellas, C.; Fern; ndez-Novoa, L.; pez-Mu; oz, F. Mediators of

Inflammation 2016, 2016, 10.
(2)

Rocha, S. M.; Pires, J.; Esteves, M.; Graça, B.; Bernardino, L. Frontiers in

Cellular Neuroscience 2014, 8.
(3)

Passani, M. B.; Ballerini, C. Frontiers in Systems Neuroscience 2012, 6, 32.

(4)

Rosa, A. C.; Fantozzi, R. British Journal of Pharmacology 2013, 170, 38.

(5)

Haas, H.; Panula, P. Nature reviews. Neuroscience 2003, 4, 121.

(6)

Haas, H. L.; Sergeeva, O. A.; Selbach, O. Physiological reviews 2008, 88, 1183.

(7)

Samaranayake, S.; Abdalla, A.; Robke, R.; Nijhout, H. F.; Reed, M. C.; Best, J.;

Hashemi, P. J Neurochem 2016, 138, 374.
(8)

Flik, G.; Folgering, J. H.; Cremers, T. I.; Westerink, B. H.; Dremencov, E.

Journal of molecular neuroscience : MN 2015, 56, 320.
(9)

Threlfell, S.; Cragg, S. J.; Kallo, I.; Turi, G. F.; Coen, C. W.; Greenfield, S. A.

The Journal of neuroscience : the official journal of the Society for Neuroscience 2004,
24, 8704.
(10)

Panula, P.; Nuutinen, S. Nature reviews. Neuroscience 2013, 14, 472.

(11)

Miller, A. H.; Raison, C. L. Nat Rev Immunol 2016, 16, 22.

(12)

Najjar, S.; Pearlman, D. M.; Alper, K.; Najjar, A.; Devinsky, O. Journal of

Neuroinflammation 2013, 10, 43.

116

(13)

Royal, W., 3rd; Zhang, L.; Guo, M.; Jones, O.; Davis, H.; Bryant, J. L. Journal of

neuroimmunology 2012, 247, 16.
(14)

Tran, P. B.; Miller, R. J. Nature reviews. Neuroscience 2003, 4, 444.

(15)

Kaul, M.; Lipton, S. A. Proceedings of the National Academy of Sciences of the

United States of America 1999, 96, 8212.
(16)

Lannuzel, A.; Lledo, P. M.; Lamghitnia, H. O.; Vincent, J. D.; Tardieu, M. The

European journal of neuroscience 1995, 7, 2285.
(17)

Moran, L. M.; Booze, R. M.; Webb, K. M.; Mactutus, C. F. Experimental

neurology 2013, 239, 139.
(18)

Nemeth, C. L.; Glasper, E. R.; Harrell, C. S.; Malviya, S. A.; Otis, J. S.; Neigh, G.

N. PLOS ONE 2014, 9, e108399.
(19)

Owens, M. J.; Nemeroff, C. B. Clinical chemistry 1994, 40, 288.

(20)

Delgado, P. L.; Charney, D. S.; Price, L. H.; Aghajanian, G. K.; Landis, H.;

Heninger, G. R. Archives of general psychiatry 1990, 47, 411.
(21)

Samaranayake, S.; Abdalla, A.; Robke, R.; Wood, K. M.; Zeqja, A.; Hashemi, P.

Analyst 2015, 140, 3759.
(22)

Hashemi, P.; Dankoski, E. C.; Petrovic, J.; Keithley, R. B.; Wightman, R. M.

Analytical Chemistry 2009, 81, 9462.
(23)

Vigorito, M.; Connaghan, K. P.; Chang, S. L. Brain, Behavior, and Immunity

2015, 48, 336.
(24)

Reid, W.; Sadowska, M.; Denaro, F.; Rao, S.; Foulke, J.; Hayes, N.; Jones, O.;

Doodnauth, D.; Davis, H.; Sill, A.; O'Driscoll, P.; Huso, D.; Fouts, T.; Lewis, G.; Hill,

117

M.; Kamin-Lewis, R.; Wei, C.; Ray, P.; Gallo, R. C.; Reitz, M.; Bryant, J. Proceedings of
the National Academy of Sciences 2001, 98, 9271.
(25)

Peng, J.; Vigorito, M.; Liu, X.; Zhou, D.; Wu, X.; Chang, S. L. Journal of

neuroimmunology 2010, 218, 94.
(26)

Mazzucchelli, R.; Amadio, M.; Curreli, S.; Denaro, F.; Bemis, K.; Reid, W.;

Bryant, J.; Riva, A.; Galli, M.; Zella, D. Molecular immunology 2004, 41, 979.
(27)

June, H. L.; Yang, A. R. S. T.; Bryant, J. L.; Jones, O.; Royal, W. Journal of

neurovirology 2009, 15, 380.
(28)

Royal, W.; Iii; Wang, H.; Jones, O.; Tran, H.; Bryant, J. L. Journal of

neuroimmunology 2007, 185, 29.
(29)

Braathen, L. R.; Ramirez, G.; Kunze, R. O. F.; Gelderblom, H. The Lancet 1987,

330, 1094.
(30)

Meltzer, M. S.; Skillman, D. R.; Gomatos, P. J.; Kalter, D. C.; Gendelman, H. E.

Annual review of immunology 1990, 8, 169.
(31)

Polazzi, E.; Monti, B. Progress in neurobiology 2010, 92, 293.

(32)

Ferreira, R.; Santos, T.; Goncalves, J.; Baltazar, G.; Ferreira, L.; Agasse, F.;

Bernardino, L. J Neuroinflammation 2012, 9, 90.
(33)

Gilfillan, A. M.; Austin, S. J.; Metcalfe, D. D. Advances in experimental medicine

and biology 2011, 716, 2.
(34)

Khalil, M.; Ronda, J.; Weintraub, M.; Jain, K.; Silver, R.; Silverman, A.-J. Brain

research 2007, 1171, 18.
(35)

Florenzano, F.; Bentivoglio, M. The Journal of comparative neurology 2000, 424,

651.

118

(36)

Silverman, A. J.; Sutherland, A. K.; Wilhelm, M.; Silver, R. The Journal of

neuroscience : the official journal of the Society for Neuroscience 2000, 20, 401.
(37)

Dong, H.; Zhang, X.; Qian, Y. Medical Science Monitor Basic Research 2014, 20,

200.
(38)

Schlicker, E.; Betz, R.; Gothert, M. Naunyn Schmiedebergs Arch Pharmacol

1988, 337, 588.
(39)

Brites, D.; Fernandes, A. Frontiers in Cellular Neuroscience 2015, 9, 476.

(40)

Morgan, D. G.; May, P. C.; Finch, C. E. Journal of the American Geriatrics

Society 1987, 35, 334.
(41)

Gardner, A.; Boles, R. G. Progress in neuro-psychopharmacology & biological

psychiatry 2011, 35, 730.
(42)

Hurley, L. L.; Tizabi, Y. Neurotoxicity research 2013, 23, 131.

119

CHAPTER 7
CONCLUSIONS AND PROSPECTS
Histamine and serotonin are important biogenic amines that regulate a variety of
brain functions. These two chemical messengers are thought to modulate each other, but
their fundamental neuromodulation mechanisms are not well understood, making such
brain disorders difficult to diagnose and treat. However, studying the underlying
neurochemistry of histamine and serotonin has been challenging due to the absence of
suitable analytical techniques. This dissertation introduced a systematic approach to
overcome this challenge.
In this dissertation, I first used Cu(II) metal analysis to understand the adsorption
driven FSCV response. We described that adsorption of Cu(II) onto CFMs follows a
monolayer Langmuir adsorption isotherm. I then used the adsorption phenomenon to
established a novel FSCV method to selectively and sensitively monitor histamine
neurotransmission in the mouse PH. In this method, electrically evoked histamine was
measured in the PH upon stimulation in the MFB. This work was extended to
simultaneously monitor in vivo histamine and serotonin in real time. This work revealed
that histamine potently inhibits serotonin in a concentration dependent manner,
highlighting histamine’s roles in regulating serotonin release in the brain. Additionally,
pharmacological and mathematical models proved that this inhibitory mechanism is
mediated by the H3 receptors. Following that, I utilized our novel method to study
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histamine’s reuptake mechanism via monoamine transporter proteins by pharmacological
manipulations. I demonstrated that the histamine uptake mechanism is mediated by OCT.
Interestingly, the histamine reuptake mechanism was also inhibited by escitalopram and
citalopram which are commercially available antidepressant drugs. Transporter inhibitory
drugs elevate extracellular serotonin, which is in turn inhibited by increased histamine via
H3 receptors. Finally, I utilized FSCV to measure serotonin and histamine
neurotransmissions in HIV-1 Tg rats, which display neuroinflammation, to investigate
neurochemical changes in the disease state. In this study, both stimulated release of
histamine and inverse regulation of serotonin were enhanced in HIV-1 Tg rats when
compared to the control animals.
Future studies will be required for the in-depth understanding of fundamental
neurochemical changes that happen during neuroinflammation. The preliminary
observations that we obtained with HIV-1 Tg rats (chapter 6) suggest that histamine plays
a vital role in inversely regulating serotonin release in the brain during
neuroinflammation. Since neuroinflammation is comorbid with various brain disorders
like depression, more pharmacological, animal model, and behavior experiments are
necessary to establish the histamine hypothesis.
In chapter 4, we illustrated the simplest version of the mathematical model, which
explains the FSCV response related to fundamental physiological functions for histamine
and serotonin. More experiments are required to expand this original mathematical model
with the ultimate goal of applying the model in brain diseases. This goal can be achieved
by pharmacological manipulations of histamine and serotonin neurochemistry. This
mathematical model will then provide essential information about impaired
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neurochemistry during any disease state, and this information can be subsequently used
to develop more effective therapies and drugs for histamine and serotonin related brain
disorders.
Collectively, this dissertation showcased a novel, powerful FSCV method for
simultaneous detection of in vivo histamine and serotonin in real time. The advancement
of this approach facilitates the systematic study of the histaminergic modulation of
serotonin in a variety of neurochemical processes and brain diseases, stressing the
potential role of histamine.
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